1
|
Iyer DR, Venkatraman J, Tanguy E, Vitale N, Mahapatra NR. Chromogranin A and its derived peptides: potential regulators of cholesterol homeostasis. Cell Mol Life Sci 2023; 80:271. [PMID: 37642733 PMCID: PMC11072126 DOI: 10.1007/s00018-023-04908-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2023] [Revised: 08/02/2023] [Accepted: 08/03/2023] [Indexed: 08/31/2023]
Abstract
Chromogranin A (CHGA), a member of the granin family of proteins, has been an attractive therapeutic target and candidate biomarker for several cardiovascular, neurological, and inflammatory disorders. The prominence of CHGA stems from the pleiotropic roles of several bioactive peptides (e.g., catestatin, pancreastatin, vasostatins) generated by its proteolytic cleavage and by their wide anatomical distribution. These peptides are emerging as novel modulators of cardiometabolic diseases that are often linked to high blood cholesterol levels. However, their impact on cholesterol homeostasis is poorly understood. The dynamic nature of cholesterol and its multitudinous roles in almost every aspect of normal body function makes it an integral component of metabolic physiology. A tightly regulated coordination of cholesterol homeostasis is imperative for proper functioning of cellular and metabolic processes. The deregulation of cholesterol levels can result in several pathophysiological states. Although studies till date suggest regulatory roles for CHGA and its derived peptides on cholesterol levels, the mechanisms by which this is achieved still remain unclear. This review aims to aggregate and consolidate the available evidence linking CHGA with cholesterol homeostasis in health and disease. In addition, we also look at common molecular regulatory factors (viz., transcription factors and microRNAs) which could govern the expression of CHGA and genes involved in cholesterol homeostasis under basal and pathological conditions. In order to gain further insights into the pathways mediating cholesterol regulation by CHGA/its derived peptides, a few prospective signaling pathways are explored, which could act as primers for future studies.
Collapse
Affiliation(s)
- Dhanya R Iyer
- Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, 600036, India
| | - Janani Venkatraman
- Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, 600036, India
| | - Emeline Tanguy
- Institut des Neurosciences Cellulaires et Intégratives, CNRS UPR 3212 and Université de Strasbourg, 5 Rue Blaise Pascal, 67000, Strasbourg, France
| | - Nicolas Vitale
- Institut des Neurosciences Cellulaires et Intégratives, CNRS UPR 3212 and Université de Strasbourg, 5 Rue Blaise Pascal, 67000, Strasbourg, France.
| | - Nitish R Mahapatra
- Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, 600036, India.
| |
Collapse
|
2
|
Qiu Z, Fan Y, Wang Z, Huang F, Li Z, Sun Z, Hua S, Jin W, Chen Y. Catestatin Protects Against Diastolic Dysfunction by Attenuating Mitochondrial Reactive Oxygen Species Generation. J Am Heart Assoc 2023; 12:e029470. [PMID: 37119063 PMCID: PMC10227223 DOI: 10.1161/jaha.123.029470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/11/2023] [Accepted: 03/30/2023] [Indexed: 04/30/2023]
Abstract
Background Catestatin has been reported as a pleiotropic cardioprotective peptide. Heart failure with preserved ejection fraction (HFpEF) was considered a heterogeneous syndrome with a complex cause. We sought to investigate the role of catestatin in HFpEF and diastolic dysfunction. METHODS AND RESULTS Administration of recombinant catestatin (1.5 mg/kg/d) improved diastolic dysfunction and left ventricular chamber stiffness in transverse aortic constriction mice with deoxycorticosterone acetate pellet implantation, as reflected by Doppler tissue imaging and pressure-volume loop catheter. Less cardiac hypertrophy and myocardial fibrosis was observed, and transcriptomic analysis revealed downregulation of mitochondrial electron transport chain components after catestatin treatment. Catestatin reversed mitochondrial structural and respiratory chain component abnormality, decreased mitochondrial proton leak, and reactive oxygen species generation in myocardium. Excessive oxidative stress induced by Ru360 abolished catestatin treatment effects on HFpEF-like cardiomyocytes in vitro, indicating the beneficial role of catestatin in HFpEF as a mitochondrial ETC modulator. The serum concentration of catestatin was tested among 81 patients with HFpEF and 76 non-heart failure controls. Compared with control subjects, serum catestatin concentration was higher in patients with HFpEF and positively correlated with E velocity to mitral annular e' velocity ratio, indicating a feedback compensation role of catestatin in HFpEF. Conclusions Catestatin protects against diastolic dysfunction in HFpEF through attenuating mitochondrial electron transport chain-derived reactive oxygen species generation. Serum catestatin concentration is elevated in patients with HFpEF, probably as a relatively insufficient but self-compensatory mechanism.
Collapse
Affiliation(s)
- Zeping Qiu
- Department of Cardiovascular Medicine, Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiPeople’s Republic of China
- Institute of Cardiovascular DiseasesShanghai Jiao Tong University School of MedicineShanghaiPeople’s Republic of China
| | - Yingze Fan
- Department of Cardiovascular Medicine, Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiPeople’s Republic of China
- Institute of Cardiovascular DiseasesShanghai Jiao Tong University School of MedicineShanghaiPeople’s Republic of China
| | - Zhiyan Wang
- Department of Cardiovascular Medicine, Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiPeople’s Republic of China
- Institute of Cardiovascular DiseasesShanghai Jiao Tong University School of MedicineShanghaiPeople’s Republic of China
| | - Fanyi Huang
- Department of Cardiovascular Medicine, Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiPeople’s Republic of China
- Institute of Cardiovascular DiseasesShanghai Jiao Tong University School of MedicineShanghaiPeople’s Republic of China
| | - Zhuojin Li
- Department of Cardiovascular Medicine, Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiPeople’s Republic of China
- Institute of Cardiovascular DiseasesShanghai Jiao Tong University School of MedicineShanghaiPeople’s Republic of China
| | - Zhihong Sun
- Department of Cardiovascular Medicine, Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiPeople’s Republic of China
- Institute of Cardiovascular DiseasesShanghai Jiao Tong University School of MedicineShanghaiPeople’s Republic of China
| | - Sha Hua
- Institute of Cardiovascular DiseasesShanghai Jiao Tong University School of MedicineShanghaiPeople’s Republic of China
- Heart Failure Center, Ruijin Hospital, & Lu Wan BranchShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Wei Jin
- Department of Cardiovascular Medicine, Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiPeople’s Republic of China
- Institute of Cardiovascular DiseasesShanghai Jiao Tong University School of MedicineShanghaiPeople’s Republic of China
- Heart Failure Center, Ruijin Hospital, & Lu Wan BranchShanghai Jiao Tong University School of MedicineShanghaiChina
| | - Yanjia Chen
- Department of Cardiovascular Medicine, Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghaiPeople’s Republic of China
- Institute of Cardiovascular DiseasesShanghai Jiao Tong University School of MedicineShanghaiPeople’s Republic of China
| |
Collapse
|
3
|
Serum Catestatin Concentrations Are Increased in Patients with Atrial Fibrillation. J Cardiovasc Dev Dis 2023; 10:jcdd10020085. [PMID: 36826581 PMCID: PMC9965955 DOI: 10.3390/jcdd10020085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2022] [Revised: 01/25/2023] [Accepted: 02/14/2023] [Indexed: 02/19/2023] Open
Abstract
The autonomic nervous system is crucial in initiating and maintaining atrial fibrillation (AF). Catestatin is a multipurpose peptide that regulates cardiovascular systems and reduces harmful, excessive activity of the sympathetic nervous system by blocking the release of catecholamines. We aimed to determine whether serum catestatin concentrations are associated with AF severity, duration indices, and various clinical and laboratory indicators in these individuals to better define the clinical value of catestatin in patients with AF. The present single center study enrolled 73 participants with AF and 72 healthy age-matched controls. Serum catestatin concentrations were markedly higher in AF patients than controls (14.11 (10.21-26.02) ng/mL vs. 10.93 (5.70-20.01) ng/mL, p = 0.013). Furthermore, patients with a more severe form of AF had significantly higher serum catestatin (17.56 (12.80-40.35) vs. 10.98 (8.38-20.91) ng/mL, p = 0.001). Patients with higher CHA2DS2-VASc scores (17.58 (11.89-37.87) vs. 13.02 (8.47-22.75) ng/mL, p = 0.034) and higher NT-proBNP levels (17.58 (IQR 13.91-34.62) vs. 13.23 (IQR 9.04-22.61), p = 0.036) had significantly higher serum catestatin concentrations. Finally, AF duration correlated negatively with serum catestatin levels (r = -0.348, p = 0.003). The results of the present study implicate the promising role of catestatin in the intricate pathophysiology of AF, which should be explored in future research.
Collapse
|
4
|
Yan M, Liu T, Zhong P, Xiong F, Cui B, Wu J, Wu G. Chronic catestatin treatment reduces atrial fibrillation susceptibility via improving calcium handling in post-infarction heart failure rats. Peptides 2023; 159:170904. [PMID: 36375660 DOI: 10.1016/j.peptides.2022.170904] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/06/2022] [Revised: 11/09/2022] [Accepted: 11/10/2022] [Indexed: 11/13/2022]
Abstract
BACKGROUND Abnormal Ca2+ handling is a pivotal element of atrial fibrillation (AF) substrates. Catestatin (CST) modulates intracellular Ca2+ handling in cardiomyocytes (CMs). We investigated the effects of CST administration on atrial Ca2+ handling and AF susceptibility in rats with post-infarction heart failure (HF). METHODS Myocardial infarction (MI) was established by ligation of the left anterior descending coronary artery in rats. Two-week later, rats with post-infarction HF were randomly treated with saline (MI group) or CST (MI + CST group) for 4-week. Cellular Ca2+ imaging was performed by incubating atrial CMs with Fura-2 AM. An in vitro electrophysiological study was performed to assess the vulnerability to action potential duration (APD) alternans and AF. Ca2+ handling proteins expression was determined using western blotting. RESULTS In atrial CMs, compared with the sham group, the sarcoplasmic reticulum (SR) Ca2+ load, Ca2+ transient (CaT) amplitude, and threshold for Ca2+ alternans were significantly decreased, but the diastolic intracellular Ca2+ level, SR Ca2+ leakage, and spontaneous Ca2+ events were markedly increased in the MI group. However, CST attenuated these Ca2+-handling abnormalities induced by post-infarction HF. Moreover, vulnerability to atrial APD alternans and AF was significantly increased in isolated hearts from the MI group compared to the sham group, whereas all effects were prevented by CST. CST treatment also preserved SR Ca2+-ATPase protein expression but decreased the protein levels of phosphorylated-ryanodine receptor 2 and phosphorylated-Ca2+/calmodulin-dependent protein kinase II in atria from post-infarction HF rats. CONCLUSION Chronic CST treatment reduces AF vulnerability in rats with MI-induced HF by improving Ca2+ handling.
Collapse
Affiliation(s)
- Min Yan
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Cardiology, Wuhan 430060, China
| | - Tao Liu
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Cardiology, Wuhan 430060, China.
| | - Peng Zhong
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Cardiology, Wuhan 430060, China.
| | - Feng Xiong
- Montreal Heart Institute, Department of Medicine, University of Montreal, Montreal H1T 1C8, Quebec, Canada; Department of Pharmacology and Therapeutics, McGill University, Montreal H3G 1Y6, Quebec, Canada
| | - Bo Cui
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Cardiology, Wuhan 430060, China
| | - Jinchun Wu
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Cardiology, Wuhan 430060, China
| | - Gang Wu
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; Cardiovascular Research Institute, Wuhan University, Wuhan 430060, China; Hubei Key Laboratory of Cardiology, Wuhan 430060, China.
| |
Collapse
|
5
|
Alieva AM, Teplova NV, Reznik EV, Ettinger OA, Faradzhov RA, Khachirova EA, Kovtiukh IV, Kotikova IA, Sysoeva DA, Bigushev IR, Nikitin IG. Catestanin – a promising biological marker for heart failure: A review. CONSILIUM MEDICUM 2022. [DOI: 10.26442/20751753.2022.10.201873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
The epidemic of heart failure (HF) is one of the problems that the global health system has been facing for decades. HF is a multicomponent clinical syndrome caused by dysfunction of the heart and its pathological remodeling. In addition to the well-known natriuretic peptides, a number of cardiovascular biological markers have now been identified that provide clinicians with additional opportunities in diagnosing, classifying, predicting, and monitoring the effectiveness of treating patients with HF. From the position of establishing the sympathetic load in patients with HF, it seems very promising to assess the concentrations of catestatin. The presented data of our literature review suggest that catestatin is probably a reliable biological marker of the activity of the sympathetic division of the autonomic nervous system, and its elevated concentrations in patients with HF reflect the severity of the pathological process. However, despite the reliable results of studies, the clinical significance of assessing the values of this marker both separately and in the framework of a multimarker model requires further study in larger prospective clinical studies.
Collapse
|
6
|
Prognostic Value of Catestatin in Severe COVID-19: An ICU-Based Study. J Clin Med 2022; 11:jcm11154496. [PMID: 35956112 PMCID: PMC9369405 DOI: 10.3390/jcm11154496] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2022] [Revised: 07/29/2022] [Accepted: 07/29/2022] [Indexed: 02/04/2023] Open
Abstract
Catestatin is a pleiotropic peptide with a wide range of immunomodulatory effects. Considering that patients with a severe COVID-19 infection have a major immunological dysregulation, the aim of this study was to evaluate catestatin levels in patients with COVID-19 treated in the intensive care unit (ICU) and to compare them between the fatal and non-fatal outcomes. The study included 152 patients with severe COVID-19, out of which 105 had a non-fatal outcome and 47 had a fatal outcome. Serum catestatin levels were estimated by an enzyme-linked immunosorbent assay in a commercially available diagnostic kit. The results show that catestatin levels were significantly lower in the fatal group compared to the non-fatal group (16.6 ± 7.8 vs. 23.2 ± 9.2 ng/mL; p < 0.001). Furthermore, there was a significant positive correlation between serum catestatin levels and vitamin D levels (r = 0.338; p < 0.001) while there was also a significant positive correlation between serum catestatin levels and growth differentiation factor-15 (GDF-15) levels (r = −0.345; p < 0.001). Furthermore, multivariate logistic regression showed that catestatin, GDF-15 and leukocyte count were significant predictors for COVID-19 survival. These findings imply that catestatin could be playing a major immunomodulatory role in the complex pathophysiology of the COVID-19 infection and that serum catestatin could also be a predictor of a poor COVID-19 outcome.
Collapse
|
7
|
Catestatin as a Biomarker of Cardiovascular Diseases: A Clinical Perspective. Biomedicines 2021; 9:biomedicines9121757. [PMID: 34944578 PMCID: PMC8698910 DOI: 10.3390/biomedicines9121757] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2021] [Revised: 11/22/2021] [Accepted: 11/23/2021] [Indexed: 02/07/2023] Open
Abstract
Accounting for almost one-third of the global mortality, cardiovascular diseases (CVDs) represent a major global health issue. Emerging data suggest that most of the well-established mechanistic explanations regarding the cardiovascular pathophysiology are flawed, and cannot fully explain the progression and long-term effects of these diseases. On the other hand, dysregulation of the sympathetic nervous system (SNS) has emerged as an important player in the pathophysiology of CVDs. Even though upregulated SNS activity is an essential compensatory response to various stress conditions, in the long term, it becomes a major contributor to both cardiac dysfunction and vascular damage. Despite the fact that the importance of SNS hyperactivity in the setting of CVDs has been well-appreciated, its exact quantification and clinical application in either diagnostics or therapy of CVDs is still out of reach. Nevertheless, in recent years a number of novel laboratory biomarkers implicated in the pathophysiology of SNS activation have been explored. Specifically, in this review, we aimed to discuss the role of catestatin, a potent physiological inhibitor of catecholamine spillover that offers cardioprotective effects. Limited data indicate that catestatin could also be a reliable indirect marker of SNS activity and it is likely that high CST levels reflect advanced CV disease burden. Consequently, large-scale studies are required to validate these observations in the upcoming future.
Collapse
|
8
|
Plasma catestatin level predicts sPESI score and mortality in acute pulmonary embolism. ARCHIVES OF MEDICAL SCIENCES. ATHEROSCLEROTIC DISEASES 2020; 5:e49-e56. [PMID: 32529106 PMCID: PMC7277442 DOI: 10.5114/amsad.2020.95562] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/23/2019] [Accepted: 04/18/2020] [Indexed: 01/22/2023]
Abstract
INTRODUCTION Acute pulmonary embolism (APE) is an emergent cardiothoracic disorder. The PESI score is used to estimate 30-day mortality in patients diagnosed with non-high-risk APE. Also, there are biomarkers for predicting prognosis and mortality in APE. Catestatin (CST) is accepted as a marker ofsympathetic nervous system activity which has been shown that the sympathetic nervous system activation can contribute pathogenesis in APE. So, we attempt herein to investigate the correlation of PE diagnosis and prognostic determination with plasma CST levels in PE patients. MATERIAL AND METHODS Blood samples were drawn at admission for laboratory assays and CST measurements. Plasma levels of CST were measured by ELISA according to the manufacturer's instruction. Transthoracic echocardiography was performed for the assessment of RV dysfunction using a Toshiba Applio 500 echocardiographic system within 24 h of the admission. RESULTS Plasma CST levels were higher in patients with APE than in the control group (17.5 ±6.1 ng/ml vs. 27.3 ±5.7 ng/ml, p < 0.001). Plasma CST levels were higher in the sPESI ≥ 1 (n = 72) than in the patients with sPESI < 1 (37.3 ±6.1 vs. 24.2 ±5.3 ng/ml, p < 0.001). There was a positive correlation between CST level and sPESI score (±0.581, p < 0.001). Mortality occurred in 20 patients with sPESI ≥ 1 (27.7%) and in 9 patients with sPESI < 1 (10.2%) (p = 0.010). Receiver operating characteristic (ROC) curve analysis using a cut-off level of 31.2 ng/ml, and the CST level predicted mortality with a sensitivity of 100% and specificity of 52.6% (AUC = 0.883, 95% CI: 0.689-0.921). Furthermore, the CST level was correlated with right ventricular dysfunction. CONCLUSIONS CST can predict sPESI score and mortality in patients with APE.
Collapse
|
9
|
Chu SY, Peng F, Wang J, Liu L, Meng L, Zhao J, Han XN, Ding WH. Catestatin in defense of oxidative-stress-induced apoptosis: A novel mechanism by activating the beta2 adrenergic receptor and PKB/Akt pathway in ischemic-reperfused myocardium. Peptides 2020; 123:170200. [PMID: 31730792 DOI: 10.1016/j.peptides.2019.170200] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/18/2019] [Revised: 11/09/2019] [Accepted: 11/11/2019] [Indexed: 02/07/2023]
Abstract
Apoptosis induced by oxidative stress is one of the most important cardiomyocytes losses during ischemia-reperfusion (I/R). Catestatin (CST) has been demonstrated to have the anti-oxidative capacity in vitro. We hypothesized that CST intervention could reduce apoptosis of cardiomyocytes induced by oxidative stress in I/R. In Langendorff-perfused rat heart global I/R model, CST was introduced at the reperfusion stage. In comparison to the control group, CST led to preservation on activities of superoxide dismutase and glutathione peroxidase, improvement of hemodynamics, and reduced infarction area in reperfused myocardium. The protection of CST was also shown by less apoptotic cardiomyocytes in TUNEL staining, less caspase-3 activation, and increased phosphorylation of protein kinase B (PKB/Akt) in Western blot. To further demonstrate the benefits of CST and explore the possible underlying mechanism, H2O2-challenged primary-cultured neonatal rat cardiomyocytes were used to simulate the oxidative-stressed scenario. CST incubation with the H2O2-challenged cardiomyocytes led to reduction of apoptosis, which was demonstrated by less Hoechst 33342 positive staining of nuclei, less caspase-3 activation, and DNA fragmentation. The effect of CST was abrogated by pretreatment of the cardiomyocytes with the PI3K inhibitor LY294002. Furthermore, Akt activation and the anti-apoptosis effect of CST were abolished by pretreatment of the cardiomyocytes with β2 receptor inhibitor ICI118551. Thus, the salvage of oxidative-stress-induced apoptotic cardiomyocytes in I/R by CST might involve activation β2 receptor and regulation of PI3K/Akt signaling in reperfusion injury salvage kinase (RISK) pathway.
Collapse
Affiliation(s)
- Song-Yun Chu
- Department of Cardiology, Peking University First Hospital, 100034, Beijing, China
| | - Fen Peng
- Department of Cardiology, Peking University First Hospital, 100034, Beijing, China; Department of Cardiology, Renmin Hospital of Wuhan University, 430060, Wuhan, China
| | - Jie Wang
- Department of Cardiology, Peking University First Hospital, 100034, Beijing, China
| | - Lin Liu
- Department of Cardiology, Peking University First Hospital, 100034, Beijing, China
| | - Lei Meng
- Department of Cardiology, Peking University First Hospital, 100034, Beijing, China
| | - Jing Zhao
- Department of Cardiology, Peking University First Hospital, 100034, Beijing, China
| | - Xiao-Ning Han
- Department of Cardiology, Peking University First Hospital, 100034, Beijing, China
| | - Wen-Hui Ding
- Department of Cardiology, Peking University First Hospital, 100034, Beijing, China.
| |
Collapse
|
10
|
Mahata SK, Corti A. Chromogranin A and its fragments in cardiovascular, immunometabolic, and cancer regulation. Ann N Y Acad Sci 2019; 1455:34-58. [PMID: 31588572 PMCID: PMC6899468 DOI: 10.1111/nyas.14249] [Citation(s) in RCA: 53] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2019] [Revised: 09/09/2019] [Accepted: 09/13/2019] [Indexed: 12/11/2022]
Abstract
Chromogranin A (CgA)-the index member of the chromogranin/secretogranin secretory protein family-is ubiquitously distributed in endocrine, neuroendocrine, and immune cells. Elevated levels of CgA-related polypeptides, consisting of full-length molecules and fragments, are detected in the blood of patients suffering from neuroendocrine tumors, heart failure, renal failure, hypertension, rheumatoid arthritis, and inflammatory bowel disease. Full-length CgA and various CgA-derived peptides, including vasostatin-1, pancreastatin, catestatin, and serpinin, are expressed at different relative levels in normal and pathological conditions and exert diverse, and sometime opposite, biological functions. For example, CgA is overexpressed in genetic hypertension, whereas catestatin is diminished. In rodents, the administration of catestatin decreases hypertension, cardiac contractility, obesity, atherosclerosis, and inflammation, and it improves insulin sensitivity. By contrast, pancreastatin is elevated in diabetic patients, and the administration of this peptide to obese mice decreases insulin sensitivity and increases inflammation. CgA and the N-terminal fragment of vasostatin-1 can enhance the endothelial barrier function, exert antiangiogenic effects, and inhibit tumor growth in animal models, whereas CgA fragments lacking the CgA C-terminal region promote angiogenesis and tumor growth. Overall, the CgA system, consisting of full-length CgA and its fragments, is emerging as an important and complex player in cardiovascular, immunometabolic, and cancer regulation.
Collapse
Affiliation(s)
- Sushil K Mahata
- VA San Diego Healthcare System, San Diego, California.,Metabolic Physiology & Ultrastructural Biology Laboratory, Department of Medicine, University of California, San Diego, La Jolla, California
| | - Angelo Corti
- IRCCS San Raffaele Scientific Institute, San Raffaele Vita-Salute University, Milan, Italy
| |
Collapse
|
11
|
Catestatin in Acutely Decompensated Heart Failure Patients: Insights from the CATSTAT-HF Study. J Clin Med 2019; 8:jcm8081132. [PMID: 31366074 PMCID: PMC6722699 DOI: 10.3390/jcm8081132] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2019] [Revised: 07/25/2019] [Accepted: 07/29/2019] [Indexed: 12/16/2022] Open
Abstract
The role of catestatin (CST) in acutely decompensated heart failure (ADHF) and myocardial infarction (MI) is poorly elucidated. Due to the implicated role of CST in the regulation of neurohumoral activity, the goals of the study were to determine CST serum levels among ninety consecutively enrolled ADHF patients, with respect to the MI history and left ventricular ejection fraction (LVEF) and to examine its association with clinical, echocardiographic, and laboratory parameters. CST levels were higher among ADHF patients with MI history, compared to those without (8.94 ± 6.39 vs. 4.90 ± 2.74 ng/mL, p = 0.001). CST serum levels did not differ among patients with reduced, midrange, and preserved LVEF (7.74 ± 5.64 vs. 5.75 ± 4.19 vs. 5.35 ± 2.77 ng/mL, p = 0.143, respectively). In the multivariable linear regression analysis, CST independently correlated with the NYHA class (β = 0.491, p < 0.001), waist-to-hip ratio (WHR) (β = −0.237, p = 0.026), HbA1c (β = −0.235, p = 0.027), LDL (β = −0.231, p = 0.029), non-HDL cholesterol (β = −0.237, p = 0.026), hs-cTnI (β = −0.221, p = 0.030), and the admission and resting heart rate (β = −0.201, p = 0.036 and β = −0.242, p = 0.030), and was in positive association with most echocardiographic parameters. In conclusion, CST levels were increased in ADHF patients with MI and were overall associated with a favorable cardiometabolic profile but at the same time reflected advanced symptomatic burden (CATSTAT-HF ClinicalTrials.gov number, NCT03389386).
Collapse
|
12
|
Sahu BS, Mahata S, Bandyopadhyay K, Mahata M, Avolio E, Pasqua T, Sahu C, Bandyopadhyay GK, Bartolomucci A, Webster NJG, Van Den Bogaart G, Fischer-Colbrie R, Corti A, Eiden LE, Mahata SK. Catestatin regulates vesicular quanta through modulation of cholinergic and peptidergic (PACAPergic) stimulation in PC12 cells. Cell Tissue Res 2018; 376:51-70. [PMID: 30467710 DOI: 10.1007/s00441-018-2956-1] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2018] [Accepted: 10/30/2018] [Indexed: 12/23/2022]
Abstract
We have previously shown that the chromogranin A (CgA)-derived peptide catestatin (CST: hCgA352-372) inhibits nicotine-induced secretion of catecholamines from the adrenal medulla and chromaffin cells. In the present study, we seek to determine whether CST regulates dense core (DC) vesicle (DCV) quanta (catecholamine and chromogranin/secretogranin proteins) during acute (0.5-h treatment) or chronic (24-h treatment) cholinergic (nicotine) or peptidergic (PACAP, pituitary adenylyl cyclase activating polypeptide) stimulation of PC12 cells. In acute experiments, we found that both nicotine (60 μM) and PACAP (0.1 μM) decreased intracellular norepinephrine (NE) content and increased 3H-NE secretion, with both effects markedly inhibited by co-treatment with CST (2 μM). In chronic experiments, we found that nicotine and PACAP both reduced DCV and DC diameters and that this effect was likewise prevented by CST. Nicotine or CST alone increased expression of CgA protein and together elicited an additional increase in CgA protein, implying that nicotine and CST utilize separate signaling pathways to activate CgA expression. In contrast, PACAP increased expression of CgB and SgII proteins, with a further potentiation by CST. CST augmented the expression of tyrosine hydroxylase (TH) but did not increase intracellular NE levels, presumably due to its inability to cause post-translational activation of TH through serine phosphorylation. Co-treatment of CST with nicotine or PACAP increased quantal size, plausibly due to increased synthesis of CgA, CgB and SgII by CST. We conclude that CST regulates DCV quanta by acutely inhibiting catecholamine secretion and chronically increasing expression of CgA after nicotinic stimulation and CgB and SgII after PACAPergic stimulation.
Collapse
Affiliation(s)
- Bhavani Shankar Sahu
- Department of Integrative Biology and Physiology, University of Minnesota, Minneapolis, MN, USA. .,Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, 92093-0732, USA.
| | - Sumana Mahata
- California Institute of Technology, Pasadena, CA, USA
| | - Keya Bandyopadhyay
- Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, 92093-0732, USA
| | - Manjula Mahata
- Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, 92093-0732, USA
| | | | | | - Chinmayi Sahu
- Department of Integrative Biology and Physiology, University of Minnesota, Minneapolis, MN, USA
| | - Gautam K Bandyopadhyay
- Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, 92093-0732, USA
| | - Alessandro Bartolomucci
- Department of Integrative Biology and Physiology, University of Minnesota, Minneapolis, MN, USA
| | - Nicholas J G Webster
- Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, 92093-0732, USA.,VA San Diego Healthcare System, San Diego, CA, USA
| | | | | | - Angelo Corti
- IRCCS San Raffaele Scientific Institute, San Raffaele Vita-Salute University, Milan, Italy
| | - Lee E Eiden
- Section on Molecular Neuroscience, NIMH-IRP, Bethesda, MD, USA
| | - Sushil K Mahata
- Department of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA, 92093-0732, USA. .,VA San Diego Healthcare System, San Diego, CA, USA.
| |
Collapse
|
13
|
Imbrogno S, Filice M, Cerra MC, Gattuso A. NO, CO and H 2 S: What about gasotransmitters in fish and amphibian heart? Acta Physiol (Oxf) 2018; 223:e13035. [PMID: 29338122 DOI: 10.1111/apha.13035] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2017] [Revised: 01/08/2018] [Accepted: 01/08/2018] [Indexed: 12/25/2022]
Abstract
The gasotransmitters nitric oxide (NO), carbon monoxide (CO), and hydrogen sulphide (H2 S), long considered only toxicant, are produced in vivo during the catabolism of common biological molecules and are crucial for a large variety of physiological processes. Mounting evidence is emerging that in poikilotherm vertebrates, as in mammals, they modulate the basal performance of the heart and the response to stress challenges. In this review, we will focus on teleost fish and amphibians to highlight the evolutionary importance in vertebrates of the cardiac control elicited by NO, CO and H2 S, and the conservation of the intracellular cascades they activate. Although many gaps are still present due to discontinuous information, we will use examples obtained by studies from our and other laboratories to illustrate the complexity of the mechanisms that, by involving gasotransmitters, allow beat-to-beat, short-, medium- and long-term cardiac homoeostasis. By presenting the latest data, we will also provide a framework in which the peculiar morpho-functional arrangement of the teleost and amphibian heart can be considered as a reference tool to decipher cardiac regulatory networks which are difficult to explore using more conventional vertebrates, such as mammals.
Collapse
Affiliation(s)
- S. Imbrogno
- Department of Biology, Ecology and Earth Sciences; University of Calabria; Arcavacata di Rende; Italy
| | - M. Filice
- Department of Biology, Ecology and Earth Sciences; University of Calabria; Arcavacata di Rende; Italy
| | - M. C. Cerra
- Department of Biology, Ecology and Earth Sciences; University of Calabria; Arcavacata di Rende; Italy
| | - A. Gattuso
- Department of Biology, Ecology and Earth Sciences; University of Calabria; Arcavacata di Rende; Italy
| |
Collapse
|
14
|
|
15
|
Ottesen AH, Carlson CR, Louch WE, Dahl MB, Sandbu RA, Johansen RF, Jarstadmarken H, Bjørås M, Høiseth AD, Brynildsen J, Sjaastad I, Stridsberg M, Omland T, Christensen G, Røsjø H. Glycosylated Chromogranin A in Heart Failure: Implications for Processing and Cardiomyocyte Calcium Homeostasis. Circ Heart Fail 2017; 10:CIRCHEARTFAILURE.116.003675. [PMID: 28209766 DOI: 10.1161/circheartfailure.116.003675] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/04/2016] [Accepted: 01/11/2017] [Indexed: 01/02/2023]
Abstract
BACKGROUND Chromogranin A (CgA) levels have previously been found to predict mortality in heart failure (HF), but currently no information is available regarding CgA processing in HF and whether the CgA fragment catestatin (CST) may directly influence cardiomyocyte function. METHODS AND RESULTS CgA processing was characterized in postinfarction HF mice and in patients with acute HF, and the functional role of CST was explored in experimental models. Myocardial biopsies from HF, but not sham-operated mice, demonstrated high molecular weight CgA bands. Deglycosylation treatment attenuated high molecular weight bands, induced a mobility shift, and increased shorter CgA fragments. Adjusting for established risk indices and biomarkers, circulating CgA levels were found to be associated with mortality in patients with acute HF, but not in patients with acute exacerbation of chronic obstructive pulmonary disease. Low CgA-to-CST conversion was also associated with increased mortality in acute HF, thus, supporting functional relevance of impaired CgA processing in cardiovascular disease. CST was identified as a direct inhibitor of CaMKIIδ (Ca2+/calmodulin-dependent protein kinase IIδ) activity, and CST reduced CaMKIIδ-dependent phosphorylation of phospholamban and the ryanodine receptor 2. In line with CaMKIIδ inhibition, CST reduced Ca2+ spark and wave frequency, reduced Ca2+ spark dimensions, increased sarcoplasmic reticulum Ca2+ content, and augmented the magnitude and kinetics of cardiomyocyte Ca2+ transients and contractions. CONCLUSIONS CgA-to-CST conversion in HF is impaired because of hyperglycosylation, which is associated with clinical outcomes in acute HF. The mechanism for increased mortality may be dysregulated cardiomyocyte Ca2+ handling because of reduced CaMKIIδ inhibition.
Collapse
Affiliation(s)
- Anett Hellebø Ottesen
- From the Division of Medicine, Akershus University Hospital, Lørenskog, Norway and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., M.B.D., R.A.S., A.D.H., J.B., T.O., H.R.); Institute for Experimental Medical Research, Oslo University Hospital and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., C.R.C., W.E.L., R.A.S., H.J., I.S., G.C.); Department of Clinical Molecular Biology, Akershus University Hospital, Lørenskog, Norway and Institute for Clinical Medicine, University of Oslo, Norway (M.B.D., R.A.S.); Department of Microbiology, Oslo University Hospital, Rikshospitalet, Norway, and University of Oslo, Norway (R.F.J., M.B.); Department of Medical Sciences, Uppsala University, Sweden (M.S.)
| | - Cathrine R Carlson
- From the Division of Medicine, Akershus University Hospital, Lørenskog, Norway and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., M.B.D., R.A.S., A.D.H., J.B., T.O., H.R.); Institute for Experimental Medical Research, Oslo University Hospital and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., C.R.C., W.E.L., R.A.S., H.J., I.S., G.C.); Department of Clinical Molecular Biology, Akershus University Hospital, Lørenskog, Norway and Institute for Clinical Medicine, University of Oslo, Norway (M.B.D., R.A.S.); Department of Microbiology, Oslo University Hospital, Rikshospitalet, Norway, and University of Oslo, Norway (R.F.J., M.B.); Department of Medical Sciences, Uppsala University, Sweden (M.S.)
| | - William E Louch
- From the Division of Medicine, Akershus University Hospital, Lørenskog, Norway and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., M.B.D., R.A.S., A.D.H., J.B., T.O., H.R.); Institute for Experimental Medical Research, Oslo University Hospital and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., C.R.C., W.E.L., R.A.S., H.J., I.S., G.C.); Department of Clinical Molecular Biology, Akershus University Hospital, Lørenskog, Norway and Institute for Clinical Medicine, University of Oslo, Norway (M.B.D., R.A.S.); Department of Microbiology, Oslo University Hospital, Rikshospitalet, Norway, and University of Oslo, Norway (R.F.J., M.B.); Department of Medical Sciences, Uppsala University, Sweden (M.S.)
| | - Mai Britt Dahl
- From the Division of Medicine, Akershus University Hospital, Lørenskog, Norway and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., M.B.D., R.A.S., A.D.H., J.B., T.O., H.R.); Institute for Experimental Medical Research, Oslo University Hospital and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., C.R.C., W.E.L., R.A.S., H.J., I.S., G.C.); Department of Clinical Molecular Biology, Akershus University Hospital, Lørenskog, Norway and Institute for Clinical Medicine, University of Oslo, Norway (M.B.D., R.A.S.); Department of Microbiology, Oslo University Hospital, Rikshospitalet, Norway, and University of Oslo, Norway (R.F.J., M.B.); Department of Medical Sciences, Uppsala University, Sweden (M.S.)
| | - Ragnhild A Sandbu
- From the Division of Medicine, Akershus University Hospital, Lørenskog, Norway and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., M.B.D., R.A.S., A.D.H., J.B., T.O., H.R.); Institute for Experimental Medical Research, Oslo University Hospital and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., C.R.C., W.E.L., R.A.S., H.J., I.S., G.C.); Department of Clinical Molecular Biology, Akershus University Hospital, Lørenskog, Norway and Institute for Clinical Medicine, University of Oslo, Norway (M.B.D., R.A.S.); Department of Microbiology, Oslo University Hospital, Rikshospitalet, Norway, and University of Oslo, Norway (R.F.J., M.B.); Department of Medical Sciences, Uppsala University, Sweden (M.S.)
| | - Rune Forstrøm Johansen
- From the Division of Medicine, Akershus University Hospital, Lørenskog, Norway and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., M.B.D., R.A.S., A.D.H., J.B., T.O., H.R.); Institute for Experimental Medical Research, Oslo University Hospital and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., C.R.C., W.E.L., R.A.S., H.J., I.S., G.C.); Department of Clinical Molecular Biology, Akershus University Hospital, Lørenskog, Norway and Institute for Clinical Medicine, University of Oslo, Norway (M.B.D., R.A.S.); Department of Microbiology, Oslo University Hospital, Rikshospitalet, Norway, and University of Oslo, Norway (R.F.J., M.B.); Department of Medical Sciences, Uppsala University, Sweden (M.S.)
| | - Hilde Jarstadmarken
- From the Division of Medicine, Akershus University Hospital, Lørenskog, Norway and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., M.B.D., R.A.S., A.D.H., J.B., T.O., H.R.); Institute for Experimental Medical Research, Oslo University Hospital and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., C.R.C., W.E.L., R.A.S., H.J., I.S., G.C.); Department of Clinical Molecular Biology, Akershus University Hospital, Lørenskog, Norway and Institute for Clinical Medicine, University of Oslo, Norway (M.B.D., R.A.S.); Department of Microbiology, Oslo University Hospital, Rikshospitalet, Norway, and University of Oslo, Norway (R.F.J., M.B.); Department of Medical Sciences, Uppsala University, Sweden (M.S.)
| | - Magnar Bjørås
- From the Division of Medicine, Akershus University Hospital, Lørenskog, Norway and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., M.B.D., R.A.S., A.D.H., J.B., T.O., H.R.); Institute for Experimental Medical Research, Oslo University Hospital and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., C.R.C., W.E.L., R.A.S., H.J., I.S., G.C.); Department of Clinical Molecular Biology, Akershus University Hospital, Lørenskog, Norway and Institute for Clinical Medicine, University of Oslo, Norway (M.B.D., R.A.S.); Department of Microbiology, Oslo University Hospital, Rikshospitalet, Norway, and University of Oslo, Norway (R.F.J., M.B.); Department of Medical Sciences, Uppsala University, Sweden (M.S.)
| | - Arne Didrik Høiseth
- From the Division of Medicine, Akershus University Hospital, Lørenskog, Norway and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., M.B.D., R.A.S., A.D.H., J.B., T.O., H.R.); Institute for Experimental Medical Research, Oslo University Hospital and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., C.R.C., W.E.L., R.A.S., H.J., I.S., G.C.); Department of Clinical Molecular Biology, Akershus University Hospital, Lørenskog, Norway and Institute for Clinical Medicine, University of Oslo, Norway (M.B.D., R.A.S.); Department of Microbiology, Oslo University Hospital, Rikshospitalet, Norway, and University of Oslo, Norway (R.F.J., M.B.); Department of Medical Sciences, Uppsala University, Sweden (M.S.)
| | - Jon Brynildsen
- From the Division of Medicine, Akershus University Hospital, Lørenskog, Norway and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., M.B.D., R.A.S., A.D.H., J.B., T.O., H.R.); Institute for Experimental Medical Research, Oslo University Hospital and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., C.R.C., W.E.L., R.A.S., H.J., I.S., G.C.); Department of Clinical Molecular Biology, Akershus University Hospital, Lørenskog, Norway and Institute for Clinical Medicine, University of Oslo, Norway (M.B.D., R.A.S.); Department of Microbiology, Oslo University Hospital, Rikshospitalet, Norway, and University of Oslo, Norway (R.F.J., M.B.); Department of Medical Sciences, Uppsala University, Sweden (M.S.)
| | - Ivar Sjaastad
- From the Division of Medicine, Akershus University Hospital, Lørenskog, Norway and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., M.B.D., R.A.S., A.D.H., J.B., T.O., H.R.); Institute for Experimental Medical Research, Oslo University Hospital and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., C.R.C., W.E.L., R.A.S., H.J., I.S., G.C.); Department of Clinical Molecular Biology, Akershus University Hospital, Lørenskog, Norway and Institute for Clinical Medicine, University of Oslo, Norway (M.B.D., R.A.S.); Department of Microbiology, Oslo University Hospital, Rikshospitalet, Norway, and University of Oslo, Norway (R.F.J., M.B.); Department of Medical Sciences, Uppsala University, Sweden (M.S.)
| | - Mats Stridsberg
- From the Division of Medicine, Akershus University Hospital, Lørenskog, Norway and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., M.B.D., R.A.S., A.D.H., J.B., T.O., H.R.); Institute for Experimental Medical Research, Oslo University Hospital and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., C.R.C., W.E.L., R.A.S., H.J., I.S., G.C.); Department of Clinical Molecular Biology, Akershus University Hospital, Lørenskog, Norway and Institute for Clinical Medicine, University of Oslo, Norway (M.B.D., R.A.S.); Department of Microbiology, Oslo University Hospital, Rikshospitalet, Norway, and University of Oslo, Norway (R.F.J., M.B.); Department of Medical Sciences, Uppsala University, Sweden (M.S.)
| | - Torbjørn Omland
- From the Division of Medicine, Akershus University Hospital, Lørenskog, Norway and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., M.B.D., R.A.S., A.D.H., J.B., T.O., H.R.); Institute for Experimental Medical Research, Oslo University Hospital and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., C.R.C., W.E.L., R.A.S., H.J., I.S., G.C.); Department of Clinical Molecular Biology, Akershus University Hospital, Lørenskog, Norway and Institute for Clinical Medicine, University of Oslo, Norway (M.B.D., R.A.S.); Department of Microbiology, Oslo University Hospital, Rikshospitalet, Norway, and University of Oslo, Norway (R.F.J., M.B.); Department of Medical Sciences, Uppsala University, Sweden (M.S.)
| | - Geir Christensen
- From the Division of Medicine, Akershus University Hospital, Lørenskog, Norway and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., M.B.D., R.A.S., A.D.H., J.B., T.O., H.R.); Institute for Experimental Medical Research, Oslo University Hospital and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., C.R.C., W.E.L., R.A.S., H.J., I.S., G.C.); Department of Clinical Molecular Biology, Akershus University Hospital, Lørenskog, Norway and Institute for Clinical Medicine, University of Oslo, Norway (M.B.D., R.A.S.); Department of Microbiology, Oslo University Hospital, Rikshospitalet, Norway, and University of Oslo, Norway (R.F.J., M.B.); Department of Medical Sciences, Uppsala University, Sweden (M.S.)
| | - Helge Røsjø
- From the Division of Medicine, Akershus University Hospital, Lørenskog, Norway and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., M.B.D., R.A.S., A.D.H., J.B., T.O., H.R.); Institute for Experimental Medical Research, Oslo University Hospital and Center for Heart Failure Research, University of Oslo, Norway (A.H.O., C.R.C., W.E.L., R.A.S., H.J., I.S., G.C.); Department of Clinical Molecular Biology, Akershus University Hospital, Lørenskog, Norway and Institute for Clinical Medicine, University of Oslo, Norway (M.B.D., R.A.S.); Department of Microbiology, Oslo University Hospital, Rikshospitalet, Norway, and University of Oslo, Norway (R.F.J., M.B.); Department of Medical Sciences, Uppsala University, Sweden (M.S.).
| |
Collapse
|
16
|
Troger J, Theurl M, Kirchmair R, Pasqua T, Tota B, Angelone T, Cerra MC, Nowosielski Y, Mätzler R, Troger J, Gayen JR, Trudeau V, Corti A, Helle KB. Granin-derived peptides. Prog Neurobiol 2017; 154:37-61. [PMID: 28442394 DOI: 10.1016/j.pneurobio.2017.04.003] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2016] [Revised: 04/10/2017] [Accepted: 04/16/2017] [Indexed: 12/14/2022]
Abstract
The granin family comprises altogether 7 different proteins originating from the diffuse neuroendocrine system and elements of the central and peripheral nervous systems. The family is dominated by three uniquely acidic members, namely chromogranin A (CgA), chromogranin B (CgB) and secretogranin II (SgII). Since the late 1980s it has become evident that these proteins are proteolytically processed, intragranularly and/or extracellularly into a range of biologically active peptides; a number of them with regulatory properties of physiological and/or pathophysiological significance. The aim of this comprehensive overview is to provide an up-to-date insight into the distribution and properties of the well established granin-derived peptides and their putative roles in homeostatic regulations. Hence, focus is directed to peptides derived from the three main granins, e.g. to the chromogranin A derived vasostatins, betagranins, pancreastatin and catestatins, the chromogranin B-derived secretolytin and the secretogranin II-derived secretoneurin (SN). In addition, the distribution and properties of the chromogranin A-derived peptides prochromacin, chromofungin, WE14, parastatin, GE-25 and serpinins, the CgB-peptide PE-11 and the SgII-peptides EM66 and manserin will also be commented on. Finally, the opposing effects of the CgA-derived vasostatin-I and catestatin and the SgII-derived peptide SN on the integrity of the vasculature, myocardial contractility, angiogenesis in wound healing, inflammatory conditions and tumors will be discussed.
Collapse
Affiliation(s)
- Josef Troger
- Department of Ophthalmology, Medical University of Innsbruck, Innsbruck, Austria.
| | - Markus Theurl
- Department of Internal Medicine, Medical University of Innsbruck, Innsbruck, Austria
| | - Rudolf Kirchmair
- Department of Internal Medicine, Medical University of Innsbruck, Innsbruck, Austria
| | - Teresa Pasqua
- Department of Biology, Ecology and Earth Sciences, University of Calabria, Arcavacata di Rende, Italy
| | - Bruno Tota
- Department of Biology, Ecology and Earth Sciences, University of Calabria, Arcavacata di Rende, Italy
| | - Tommaso Angelone
- Department of Biology, Ecology and Earth Sciences, University of Calabria, Arcavacata di Rende, Italy
| | - Maria C Cerra
- Department of Biology, Ecology and Earth Sciences, University of Calabria, Arcavacata di Rende, Italy
| | - Yvonne Nowosielski
- Department of Ophthalmology, Medical University of Innsbruck, Innsbruck, Austria
| | - Raphaela Mätzler
- Department of Ophthalmology, Medical University of Innsbruck, Innsbruck, Austria
| | - Jasmin Troger
- Department of Ophthalmology, Medical University of Innsbruck, Innsbruck, Austria
| | | | - Vance Trudeau
- Department of Biology, University of Ottawa, Ottawa, Ontario, Canada
| | - Angelo Corti
- Vita-Salute San Raffaele University and Division of Experimental Oncology, San Raffaele Scientific Institute, Milan, Italy
| | - Karen B Helle
- Department of Biomedicine, University of Bergen, Norway
| |
Collapse
|
17
|
Catestatin-A Novel Predictor of Left Ventricular Remodeling After Acute Myocardial Infarction. Sci Rep 2017; 7:44168. [PMID: 28397784 PMCID: PMC5387721 DOI: 10.1038/srep44168] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2016] [Accepted: 02/01/2017] [Indexed: 01/29/2023] Open
Abstract
Catestatin was discovered as a potent inhibitor of catecholamine secretion and plays important roles in the cardiovascular system. Our previous study demonstrates a close relationship between catestatin levels and prognosis of ST-elevation myocardial infarction (STEMI). Using the same population, the goal of this study is to investigate the ability of catestatin to predict left ventricular (LV) remodeling in STEMI patients. 72 patients and 30 controls were included. Catestatin was sampled after admission to the emergency room (ER), at day3 (D3), and day7 (D7) after STEMI. Echocardiography was performed at D3 and after 65 months for evaluation of LVEDD, EF, IVS, LVPW, E, A, E’, E/A, and E/E’. The changes of these parameters from D3 to 65 months were used to reflect the changes of ventricular structure and function. We found that plasma catestatin levels at D3 were highly correlated with the changes of LVEDD, EF, E, A, E’, E/A, as well as E/E’. Patients with higher catestatin levels developed worse ventricular function during the follow-up period. Single-point catestatin was effective to predict LVEDD change. And concurrently increasing catestatin and NT-proBNP levels predicted the highest risk of LV remodeling. This study suggests an important prognostic information of catestatin on LV remodeling.
Collapse
|
18
|
Imbrogno S, Mazza R, Pugliese C, Filice M, Angelone T, Loh YP, Tota B, Cerra MC. The Chromogranin A-derived sympathomimetic serpinin depresses myocardial performance in teleost and amphibian hearts. Gen Comp Endocrinol 2017; 240:1-9. [PMID: 27633326 DOI: 10.1016/j.ygcen.2016.09.004] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/13/2016] [Revised: 09/05/2016] [Accepted: 09/11/2016] [Indexed: 02/03/2023]
Abstract
Chromogranin A (CgA) is an acidic protein co-stored with catecholamines, hormones and neuropeptides in the secretory granules of endocrine, neuronal and other cell types (including cardiomyocytes). Proteolytic cleavage in the C terminus of CgA generates a 2.9kDa peptide named serpinin (Serp; Ala26Leu) that can be modified at its N terminus to form a pyroglutamate residue (pGlu-Serp). In the rat heart, both peptides increase contractility and relaxation through a β-adrenergic-like action mechanism. Accordingly, Serp and pGlu-Serp were proposed as novel myocardial sympatho-adrenergic modulators in mammals. On a comparative basis, here we report the actions of Serp and pGlu-Serp on myocardial contractility in three poikilotherm vertebrate species: the eel (Anguilla anguilla), the goldfish (Carassius auratus) and the frog (Rana esculenta). Using isolated working heart preparations, we show that pGlu-Serp reduces stroke volume in all species tested, while Serp reduces contractility in the frog heart, but is uneffective in eel and goldfish hearts. In the goldfish and frog hearts, pGlu-Serp activates the Nitric Oxide/cGMP pathway involving Endothelin-1 B receptors (frog) and β3 adrenergic receptors (goldfish). pGlu-Serp-treated hearts from goldfish and frog show increased cGMP content. Moreover, the exposure of the frog heart to pGlu-Serp is accompanied by an increased expression of activated eNOS and Akt. In conclusion, this first report showing that pGlu-Serp inhibits mechanical cardiac performance in teleost and amphibians supports an evolutionary role of the CgA system, and particularly its serpinin component, in the sympatho-adrenergic control of the vertebrate heart.
Collapse
Affiliation(s)
- S Imbrogno
- Dept. of Biology, Ecology and Earth Sciences (B.E.S.T.), University of Calabria, Arcavacata di Rende (CS), Italy.
| | - R Mazza
- Dept. of Biology, Ecology and Earth Sciences (B.E.S.T.), University of Calabria, Arcavacata di Rende (CS), Italy
| | - C Pugliese
- Dept. of Biology, Ecology and Earth Sciences (B.E.S.T.), University of Calabria, Arcavacata di Rende (CS), Italy
| | - M Filice
- Dept. of Biology, Ecology and Earth Sciences (B.E.S.T.), University of Calabria, Arcavacata di Rende (CS), Italy
| | - T Angelone
- Dept. of Biology, Ecology and Earth Sciences (B.E.S.T.), University of Calabria, Arcavacata di Rende (CS), Italy
| | - Y P Loh
- Section on Cellular Neurobiology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA
| | - B Tota
- Dept. of Biology, Ecology and Earth Sciences (B.E.S.T.), University of Calabria, Arcavacata di Rende (CS), Italy
| | - M C Cerra
- Dept. of Biology, Ecology and Earth Sciences (B.E.S.T.), University of Calabria, Arcavacata di Rende (CS), Italy
| |
Collapse
|
19
|
Abstract
Catestatin (CST) was first named in 1997 for its catecholamine-inhibitory activity. It was discovered as a potent inhibitor of catecholamine secretion and as a regulator of histamine release. Accumulating evidence shows that CST is involved with cardiovascular diseases; however, whether CST is a protective factor for these conditions and the mechanisms by which such actions may be mediated are not well understood. In this article, we review recent basic research and clinical trials in the study of CST and summarize the association of CST with cardiovascular diseases. We review data obtained from MedLine via PubMed and from our own investigations.
Collapse
Affiliation(s)
- Yilin Zhao
- The Departments of Genetics, Albert Einstein College of Medicine, Bronx, NY 10461, USA
| | - Dan Zhu
- Department of Cardiology, Peking University Third Hospital, Key Laboratory of Cardiovascular Molecular Biology & Regulatory Peptides, Ministry of Health & Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Beijing 100191, China
| |
Collapse
|
20
|
Wang D, Liu T, Shi S, Li R, Shan Y, Huang Y, Hu D, Huang C. Chronic Administration of Catestatin Improves Autonomic Function and Exerts Cardioprotective Effects in Myocardial Infarction Rats. J Cardiovasc Pharmacol Ther 2016; 21:526-535. [PMID: 26821570 DOI: 10.1177/1074248416628676] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/24/2015] [Accepted: 11/28/2015] [Indexed: 12/20/2022]
Abstract
Catestatin (CST), which is emerging as a novel cardiac modulator, can protect the heart against excessive sympathetic drive in hypertensive cardiomyopathy. The aim of this study is to investigate whether exogenous CST decreases excessive cardiac sympathetic drive and improves autonomic function and exerts cardioprotective effects in myocardial infarction (MI) rats. Rats were divided into a sham group, MI group, and MI plus CST (MI + CST) group. Four weeks later, the autonomic function of the animals was assessed by analyzing heart rate variability (HRV) and measuring plasma catecholamine. Cardiac function was evaluated via echocardiography. Electrophysiological characteristics were assessed in Langendorff-perfused hearts. Compared to the MI group, the chronic administration of CST significantly increased the standard deviation of normal–normal intervals ( P < .01) and low-frequency (LF) and high-frequency (HF) HRV and decreased the ratio of LF–HF HRV ( P < .01 for all). Additionally, the level of plasma catecholamine was reduced in the MI + CST group compared to the MI group ( P < .01). Treatment with CST significantly increased ejection fraction (EF) and fraction shorting (FS) and significantly decreased the left ventricular end-systolic diameter and left ventricular end-diastolic diameter at 28 days postmyocardial infraction ( P < .05 for all). After MI, the ventricular repolarization duration, such as QTc intervals and action potential duration (APD) at 90% repolarization, was prolonged, and this prolongation could be decreased by CST ( P < .05 for all). The CST also increased the threshold of ADP alternans ( P < .01). Moreover, ventricular arrhythmias were induced in 83% of the MI group but only 33% of the MI + CST group ( P < .05). These results suggested that the chronic administration of CST plays a role in cardioprotection in MI rats, which may function by decreasing the cardiac sympathetic drive and improving autonomic function.
Collapse
Affiliation(s)
- Dandan Wang
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China
- Cardiovacular Research Institute, Wuhan University, Wuhan, China
| | - Tao Liu
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China
- Cardiovacular Research Institute, Wuhan University, Wuhan, China
| | - Shaobo Shi
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China
- Cardiovacular Research Institute, Wuhan University, Wuhan, China
| | - Ran Li
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China
- Cardiovacular Research Institute, Wuhan University, Wuhan, China
| | - Yingguang Shan
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China
- Cardiovacular Research Institute, Wuhan University, Wuhan, China
| | - Yan Huang
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China
- Cardiovacular Research Institute, Wuhan University, Wuhan, China
| | - Dan Hu
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China
- Cardiovacular Research Institute, Wuhan University, Wuhan, China
- Masonic Medical Research Laboratory, Utica, NY, USA
| | - Congxin Huang
- Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China
- Cardiovacular Research Institute, Wuhan University, Wuhan, China
| |
Collapse
|
21
|
Kiranmayi M, Chirasani VR, Allu PKR, Subramanian L, Martelli EE, Sahu BS, Vishnuprabu D, Kumaragurubaran R, Sharma S, Bodhini D, Dixit M, Munirajan AK, Khullar M, Radha V, Mohan V, Mullasari AS, Naga Prasad SV, Senapati S, Mahapatra NR. Catestatin Gly364Ser Variant Alters Systemic Blood Pressure and the Risk for Hypertension in Human Populations via Endothelial Nitric Oxide Pathway. Hypertension 2016; 68:334-47. [PMID: 27324226 DOI: 10.1161/hypertensionaha.116.06568] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2016] [Accepted: 05/17/2016] [Indexed: 12/13/2022]
Abstract
Catestatin (CST), an endogenous antihypertensive/antiadrenergic peptide, is a novel regulator of cardiovascular physiology. Here, we report case-control studies in 2 geographically/ethnically distinct Indian populations (n≈4000) that showed association of the naturally-occurring human CST-Gly364Ser variant with increased risk for hypertension (age-adjusted odds ratios: 1.483; P=0.009 and 2.951; P=0.005). Consistently, 364Ser allele carriers displayed elevated systolic (up to ≈8 mm Hg; P=0.004) and diastolic (up to ≈6 mm Hg; P=0.001) blood pressure. The variant allele was also found to be in linkage disequilibrium with other functional single-nucleotide polymorphisms in the CHGA promoter and nearby coding region. Functional characterization of the Gly364Ser variant was performed using cellular/molecular biological experiments (viz peptide-receptor binding assays, nitric oxide [NO], phosphorylated extracellular regulated kinase, and phosphorylated endothelial NO synthase estimations) and computational approaches (molecular dynamics simulations for structural analysis of wild-type [CST-WT] and variant [CST-364Ser] peptides and docking of peptide/ligand with β-adrenergic receptors [ADRB1/2]). CST-WT and CST-364Ser peptides differed profoundly in their secondary structures and showed differential interactions with ADRB2; although CST-WT displaced the ligand bound to ADRB2, CST-364Ser failed to do the same. Furthermore, CST-WT significantly inhibited ADRB2-stimulated extracellular regulated kinase activation, suggesting an antagonistic role towards ADRB2 unlike CST-364Ser. Consequently, CST-WT was more potent in NO production in human umbilical vein endothelial cells as compared with CST-364Ser. This NO-producing ability of CST-WT was abrogated by ADRB2 antagonist ICI 118551. In conclusion, CST-364Ser allele enhanced the risk for hypertension in human populations, possibly via diminished endothelial NO production because of altered interactions of CST-364Ser peptide with ADRB2 as compared with CST-WT.
Collapse
Affiliation(s)
- Malapaka Kiranmayi
- From the Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India (M.Kiranmayi, V.R.C., P.K.R.A., L.S., B.S.S., R.K., M.D., S.Senapati, N.R.M.); Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, OH (E.E.M., S.V.N.P.); Department of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, Tamil Nadu, India (D.V., A.K.M.); Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India (S.Sharma, M.Khullar); Department of Molecular Genetics, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India (D.B., V.R., V.M.); Institute of Cardiovascular Diseases, Madras Medical Mission, Chennai, Tamil Nadu, India (A.S.M.); Department of Medicine, University of California San Francisco (P.K.R.A.); and Department of Clinical Biochemistry, University of Cambridge, Cambridge, United Kingdom (B.S.S.)
| | - Venkat R Chirasani
- From the Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India (M.Kiranmayi, V.R.C., P.K.R.A., L.S., B.S.S., R.K., M.D., S.Senapati, N.R.M.); Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, OH (E.E.M., S.V.N.P.); Department of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, Tamil Nadu, India (D.V., A.K.M.); Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India (S.Sharma, M.Khullar); Department of Molecular Genetics, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India (D.B., V.R., V.M.); Institute of Cardiovascular Diseases, Madras Medical Mission, Chennai, Tamil Nadu, India (A.S.M.); Department of Medicine, University of California San Francisco (P.K.R.A.); and Department of Clinical Biochemistry, University of Cambridge, Cambridge, United Kingdom (B.S.S.)
| | - Prasanna K R Allu
- From the Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India (M.Kiranmayi, V.R.C., P.K.R.A., L.S., B.S.S., R.K., M.D., S.Senapati, N.R.M.); Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, OH (E.E.M., S.V.N.P.); Department of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, Tamil Nadu, India (D.V., A.K.M.); Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India (S.Sharma, M.Khullar); Department of Molecular Genetics, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India (D.B., V.R., V.M.); Institute of Cardiovascular Diseases, Madras Medical Mission, Chennai, Tamil Nadu, India (A.S.M.); Department of Medicine, University of California San Francisco (P.K.R.A.); and Department of Clinical Biochemistry, University of Cambridge, Cambridge, United Kingdom (B.S.S.)
| | - Lakshmi Subramanian
- From the Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India (M.Kiranmayi, V.R.C., P.K.R.A., L.S., B.S.S., R.K., M.D., S.Senapati, N.R.M.); Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, OH (E.E.M., S.V.N.P.); Department of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, Tamil Nadu, India (D.V., A.K.M.); Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India (S.Sharma, M.Khullar); Department of Molecular Genetics, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India (D.B., V.R., V.M.); Institute of Cardiovascular Diseases, Madras Medical Mission, Chennai, Tamil Nadu, India (A.S.M.); Department of Medicine, University of California San Francisco (P.K.R.A.); and Department of Clinical Biochemistry, University of Cambridge, Cambridge, United Kingdom (B.S.S.)
| | - Elizabeth E Martelli
- From the Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India (M.Kiranmayi, V.R.C., P.K.R.A., L.S., B.S.S., R.K., M.D., S.Senapati, N.R.M.); Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, OH (E.E.M., S.V.N.P.); Department of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, Tamil Nadu, India (D.V., A.K.M.); Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India (S.Sharma, M.Khullar); Department of Molecular Genetics, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India (D.B., V.R., V.M.); Institute of Cardiovascular Diseases, Madras Medical Mission, Chennai, Tamil Nadu, India (A.S.M.); Department of Medicine, University of California San Francisco (P.K.R.A.); and Department of Clinical Biochemistry, University of Cambridge, Cambridge, United Kingdom (B.S.S.)
| | - Bhavani S Sahu
- From the Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India (M.Kiranmayi, V.R.C., P.K.R.A., L.S., B.S.S., R.K., M.D., S.Senapati, N.R.M.); Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, OH (E.E.M., S.V.N.P.); Department of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, Tamil Nadu, India (D.V., A.K.M.); Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India (S.Sharma, M.Khullar); Department of Molecular Genetics, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India (D.B., V.R., V.M.); Institute of Cardiovascular Diseases, Madras Medical Mission, Chennai, Tamil Nadu, India (A.S.M.); Department of Medicine, University of California San Francisco (P.K.R.A.); and Department of Clinical Biochemistry, University of Cambridge, Cambridge, United Kingdom (B.S.S.)
| | - Durairajpandian Vishnuprabu
- From the Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India (M.Kiranmayi, V.R.C., P.K.R.A., L.S., B.S.S., R.K., M.D., S.Senapati, N.R.M.); Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, OH (E.E.M., S.V.N.P.); Department of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, Tamil Nadu, India (D.V., A.K.M.); Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India (S.Sharma, M.Khullar); Department of Molecular Genetics, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India (D.B., V.R., V.M.); Institute of Cardiovascular Diseases, Madras Medical Mission, Chennai, Tamil Nadu, India (A.S.M.); Department of Medicine, University of California San Francisco (P.K.R.A.); and Department of Clinical Biochemistry, University of Cambridge, Cambridge, United Kingdom (B.S.S.)
| | - Rathnakumar Kumaragurubaran
- From the Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India (M.Kiranmayi, V.R.C., P.K.R.A., L.S., B.S.S., R.K., M.D., S.Senapati, N.R.M.); Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, OH (E.E.M., S.V.N.P.); Department of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, Tamil Nadu, India (D.V., A.K.M.); Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India (S.Sharma, M.Khullar); Department of Molecular Genetics, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India (D.B., V.R., V.M.); Institute of Cardiovascular Diseases, Madras Medical Mission, Chennai, Tamil Nadu, India (A.S.M.); Department of Medicine, University of California San Francisco (P.K.R.A.); and Department of Clinical Biochemistry, University of Cambridge, Cambridge, United Kingdom (B.S.S.)
| | - Saurabh Sharma
- From the Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India (M.Kiranmayi, V.R.C., P.K.R.A., L.S., B.S.S., R.K., M.D., S.Senapati, N.R.M.); Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, OH (E.E.M., S.V.N.P.); Department of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, Tamil Nadu, India (D.V., A.K.M.); Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India (S.Sharma, M.Khullar); Department of Molecular Genetics, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India (D.B., V.R., V.M.); Institute of Cardiovascular Diseases, Madras Medical Mission, Chennai, Tamil Nadu, India (A.S.M.); Department of Medicine, University of California San Francisco (P.K.R.A.); and Department of Clinical Biochemistry, University of Cambridge, Cambridge, United Kingdom (B.S.S.)
| | - Dhanasekaran Bodhini
- From the Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India (M.Kiranmayi, V.R.C., P.K.R.A., L.S., B.S.S., R.K., M.D., S.Senapati, N.R.M.); Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, OH (E.E.M., S.V.N.P.); Department of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, Tamil Nadu, India (D.V., A.K.M.); Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India (S.Sharma, M.Khullar); Department of Molecular Genetics, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India (D.B., V.R., V.M.); Institute of Cardiovascular Diseases, Madras Medical Mission, Chennai, Tamil Nadu, India (A.S.M.); Department of Medicine, University of California San Francisco (P.K.R.A.); and Department of Clinical Biochemistry, University of Cambridge, Cambridge, United Kingdom (B.S.S.)
| | - Madhulika Dixit
- From the Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India (M.Kiranmayi, V.R.C., P.K.R.A., L.S., B.S.S., R.K., M.D., S.Senapati, N.R.M.); Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, OH (E.E.M., S.V.N.P.); Department of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, Tamil Nadu, India (D.V., A.K.M.); Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India (S.Sharma, M.Khullar); Department of Molecular Genetics, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India (D.B., V.R., V.M.); Institute of Cardiovascular Diseases, Madras Medical Mission, Chennai, Tamil Nadu, India (A.S.M.); Department of Medicine, University of California San Francisco (P.K.R.A.); and Department of Clinical Biochemistry, University of Cambridge, Cambridge, United Kingdom (B.S.S.)
| | - Arasambattu K Munirajan
- From the Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India (M.Kiranmayi, V.R.C., P.K.R.A., L.S., B.S.S., R.K., M.D., S.Senapati, N.R.M.); Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, OH (E.E.M., S.V.N.P.); Department of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, Tamil Nadu, India (D.V., A.K.M.); Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India (S.Sharma, M.Khullar); Department of Molecular Genetics, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India (D.B., V.R., V.M.); Institute of Cardiovascular Diseases, Madras Medical Mission, Chennai, Tamil Nadu, India (A.S.M.); Department of Medicine, University of California San Francisco (P.K.R.A.); and Department of Clinical Biochemistry, University of Cambridge, Cambridge, United Kingdom (B.S.S.)
| | - Madhu Khullar
- From the Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India (M.Kiranmayi, V.R.C., P.K.R.A., L.S., B.S.S., R.K., M.D., S.Senapati, N.R.M.); Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, OH (E.E.M., S.V.N.P.); Department of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, Tamil Nadu, India (D.V., A.K.M.); Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India (S.Sharma, M.Khullar); Department of Molecular Genetics, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India (D.B., V.R., V.M.); Institute of Cardiovascular Diseases, Madras Medical Mission, Chennai, Tamil Nadu, India (A.S.M.); Department of Medicine, University of California San Francisco (P.K.R.A.); and Department of Clinical Biochemistry, University of Cambridge, Cambridge, United Kingdom (B.S.S.)
| | - Venkatesan Radha
- From the Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India (M.Kiranmayi, V.R.C., P.K.R.A., L.S., B.S.S., R.K., M.D., S.Senapati, N.R.M.); Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, OH (E.E.M., S.V.N.P.); Department of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, Tamil Nadu, India (D.V., A.K.M.); Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India (S.Sharma, M.Khullar); Department of Molecular Genetics, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India (D.B., V.R., V.M.); Institute of Cardiovascular Diseases, Madras Medical Mission, Chennai, Tamil Nadu, India (A.S.M.); Department of Medicine, University of California San Francisco (P.K.R.A.); and Department of Clinical Biochemistry, University of Cambridge, Cambridge, United Kingdom (B.S.S.)
| | - Viswanathan Mohan
- From the Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India (M.Kiranmayi, V.R.C., P.K.R.A., L.S., B.S.S., R.K., M.D., S.Senapati, N.R.M.); Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, OH (E.E.M., S.V.N.P.); Department of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, Tamil Nadu, India (D.V., A.K.M.); Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India (S.Sharma, M.Khullar); Department of Molecular Genetics, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India (D.B., V.R., V.M.); Institute of Cardiovascular Diseases, Madras Medical Mission, Chennai, Tamil Nadu, India (A.S.M.); Department of Medicine, University of California San Francisco (P.K.R.A.); and Department of Clinical Biochemistry, University of Cambridge, Cambridge, United Kingdom (B.S.S.)
| | - Ajit S Mullasari
- From the Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India (M.Kiranmayi, V.R.C., P.K.R.A., L.S., B.S.S., R.K., M.D., S.Senapati, N.R.M.); Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, OH (E.E.M., S.V.N.P.); Department of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, Tamil Nadu, India (D.V., A.K.M.); Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India (S.Sharma, M.Khullar); Department of Molecular Genetics, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India (D.B., V.R., V.M.); Institute of Cardiovascular Diseases, Madras Medical Mission, Chennai, Tamil Nadu, India (A.S.M.); Department of Medicine, University of California San Francisco (P.K.R.A.); and Department of Clinical Biochemistry, University of Cambridge, Cambridge, United Kingdom (B.S.S.)
| | - Sathyamangla V Naga Prasad
- From the Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India (M.Kiranmayi, V.R.C., P.K.R.A., L.S., B.S.S., R.K., M.D., S.Senapati, N.R.M.); Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, OH (E.E.M., S.V.N.P.); Department of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, Tamil Nadu, India (D.V., A.K.M.); Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India (S.Sharma, M.Khullar); Department of Molecular Genetics, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India (D.B., V.R., V.M.); Institute of Cardiovascular Diseases, Madras Medical Mission, Chennai, Tamil Nadu, India (A.S.M.); Department of Medicine, University of California San Francisco (P.K.R.A.); and Department of Clinical Biochemistry, University of Cambridge, Cambridge, United Kingdom (B.S.S.)
| | - Sanjib Senapati
- From the Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India (M.Kiranmayi, V.R.C., P.K.R.A., L.S., B.S.S., R.K., M.D., S.Senapati, N.R.M.); Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, OH (E.E.M., S.V.N.P.); Department of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, Tamil Nadu, India (D.V., A.K.M.); Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India (S.Sharma, M.Khullar); Department of Molecular Genetics, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India (D.B., V.R., V.M.); Institute of Cardiovascular Diseases, Madras Medical Mission, Chennai, Tamil Nadu, India (A.S.M.); Department of Medicine, University of California San Francisco (P.K.R.A.); and Department of Clinical Biochemistry, University of Cambridge, Cambridge, United Kingdom (B.S.S.)
| | - Nitish R Mahapatra
- From the Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India (M.Kiranmayi, V.R.C., P.K.R.A., L.S., B.S.S., R.K., M.D., S.Senapati, N.R.M.); Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, OH (E.E.M., S.V.N.P.); Department of Genetics, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai, Tamil Nadu, India (D.V., A.K.M.); Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh, India (S.Sharma, M.Khullar); Department of Molecular Genetics, Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India (D.B., V.R., V.M.); Institute of Cardiovascular Diseases, Madras Medical Mission, Chennai, Tamil Nadu, India (A.S.M.); Department of Medicine, University of California San Francisco (P.K.R.A.); and Department of Clinical Biochemistry, University of Cambridge, Cambridge, United Kingdom (B.S.S.).
| |
Collapse
|
22
|
Catestatin attenuates endoplasmic reticulum induced cell apoptosis by activation type 2 muscarinic acetylcholine receptor in cardiac ischemia/reperfusion. Sci Rep 2015; 5:16590. [PMID: 26567709 PMCID: PMC4645123 DOI: 10.1038/srep16590] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2015] [Accepted: 10/16/2015] [Indexed: 02/06/2023] Open
Abstract
Catestatin (CST) is a catecholamine secretion inhibiting peptide as non-competitive inhibitor of nicotinic acetylcholine receptor. CST play a protective role in cardiac ischemia/reperfusion (I/R) but the molecular mechanism remains unclear. Cardiomyocytes endogenously produced CST and its expression was reduced after I/R. CST pretreatment decreased apoptosis especially endoplasmic reticulum (ER) stress response during I/R. The protection of CST was confirmed in H9c2 cardiomyoblasts under Anoxia/reoxygenation (A/R). In contrast, siRNA-mediated knockdown of CST exaggerated ER stress induced apoptosis. The protective effects of CST were blocked by extracellular signal-regulated kinases 1/2 (ERK1/2) inhibitor PD90895 and phosphoinositide 3-kinase (PI3 K) inhibitor wortmannin. CST also increased ERK1/2 and protein kinase B (Akt) phosphorylation and which was blocked by atropine and selective type 2 muscarinic acetylcholine (M2) receptor, but not type 1 muscarinic acetylcholine (M1) receptor antagonist. Receptor binding assay revealed that CST competitively bound to the M2 receptor with a 50% inhibitory concentration of 25.7 nM. Accordingly, CST inhibited cellular cAMP stimulated by isoproterenol or forskolin, and which was blocked by selective M2 receptor antagonist. Our findings revealed that CST binds to M2 receptor, then activates ERK1/2 and PI3 K/Akt pathway to inhibit ER stress-induced cell apoptosis resulting in attenuation cardiac I/R injury.
Collapse
|
23
|
Abstract
Catestatin (CST) was first discovered as a potent non-competitive and reversible inhibitor of catecholamine secretion. Recent reports on plasma CST level in heart diseases suggested a cardioprotective role for this peptide. Given that cardiac remodeling is the dominant pathologic process in cardiac dysfunction, we propose that CST participates in the regulation of concern pathways and contributes to the inhibition of cardiac remodeling. In this minireview, the potential mechanism of cardiac remodeling involving CST will be discussed from three aspects: hypertrophy, fibrosis, and apoptosis.
Collapse
Affiliation(s)
- Zheng Wu
- Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Ministry of Health and Key Laboratory of Molecular Cardiovascular Sciences, Department of Cardiology, Peking University Third Hospital, Ministry of Education , Beijing , China
| | | |
Collapse
|
24
|
Agarwal A, Goss JA, Cho A, McCain ML, Parker KK. Microfluidic heart on a chip for higher throughput pharmacological studies. LAB ON A CHIP 2013; 13:3599-608. [PMID: 23807141 PMCID: PMC3786400 DOI: 10.1039/c3lc50350j] [Citation(s) in RCA: 325] [Impact Index Per Article: 29.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
We present the design of a higher throughput "heart on a chip" which utilizes a semi-automated fabrication technique to process sub millimeter sized thin film cantilevers of soft elastomers. Anisotropic cardiac microtissues which recapitulate the laminar architecture of the heart ventricle are engineered on these cantilevers. Deflection of these cantilevers, termed Muscular Thin Films (MTFs), during muscle contraction allows calculation of diastolic and systolic stresses generated by the engineered tissues. We also present the design of a reusable one channel fluidic microdevice completely built out of autoclavable materials which incorporates various features required for an optical cardiac contractility assay: metallic base which fits on a heating element for temperature control, transparent top for recording cantilever deformation and embedded electrodes for electrical field stimulation of the tissue. We employ the microdevice to test the positive inotropic effect of isoproterenol on cardiac contractility at dosages ranging from 1 nM to 100 μM. The higher throughput fluidic heart on a chip has applications in testing of cardiac tissues built from rare or expensive cell sources and for integration with other organ mimics. These advances will help alleviate translational barriers for commercial adoption of these technologies by improving the throughput and reproducibility of readout, standardization of the platform and scalability of manufacture.
Collapse
Affiliation(s)
- Ashutosh Agarwal
- Disease Biophysics Group, Wyss Institute of Biologically Inspired Engineering, Harvard Stem Cell Institute, School of Engineering and Applied Sciences, Harvard University, 29 Oxford St, Pierce Hall Rm 321, Cambridge, MA, 02138, USA
| | - Josue Adrian Goss
- Disease Biophysics Group, Wyss Institute of Biologically Inspired Engineering, Harvard Stem Cell Institute, School of Engineering and Applied Sciences, Harvard University, 29 Oxford St, Pierce Hall Rm 321, Cambridge, MA, 02138, USA
| | - Alexander Cho
- Disease Biophysics Group, Wyss Institute of Biologically Inspired Engineering, Harvard Stem Cell Institute, School of Engineering and Applied Sciences, Harvard University, 29 Oxford St, Pierce Hall Rm 321, Cambridge, MA, 02138, USA
| | - Megan Laura McCain
- Disease Biophysics Group, Wyss Institute of Biologically Inspired Engineering, Harvard Stem Cell Institute, School of Engineering and Applied Sciences, Harvard University, 29 Oxford St, Pierce Hall Rm 321, Cambridge, MA, 02138, USA
| | - Kevin Kit Parker
- Disease Biophysics Group, Wyss Institute of Biologically Inspired Engineering, Harvard Stem Cell Institute, School of Engineering and Applied Sciences, Harvard University, 29 Oxford St, Pierce Hall Rm 321, Cambridge, MA, 02138, USA
- ; Fax: +(617) 495-9837; Tel: +(617) 495-2850
| |
Collapse
|
25
|
Liu L, Ding W, Li R, Ye X, Zhao J, Jiang J, Meng L, Wang J, Chu S, Han X, Peng F. Plasma levels and diagnostic value of catestatin in patients with heart failure. Peptides 2013; 46:20-5. [PMID: 23702300 DOI: 10.1016/j.peptides.2013.05.003] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/08/2013] [Revised: 05/11/2013] [Accepted: 05/13/2013] [Indexed: 02/06/2023]
Abstract
Catestatin (CST) is an endogenous neuropeptide with multiple cardiovascular activities. The study is to investigate circulating CST levels in heart failure (HF) patients and to evaluate the role of CST as a biomarker for HF. Plasma CST concentrations were measured by enzyme-linked immunosorbent assay in 228 HF patients and 172 controls. Plasma CST gradually increased in patients from NYHA class I to class IV. No significant differences in CST were found among NYHA I, NYHA II patients and controls. Plasma CST in NYHA III and IV patients was higher compared to other groups. Plasma CST levels in HF patients after treatment were similar to admission, but still higher than controls. In a subgroup analysis among the patients with NYHA class III or IV, patients with ischemic etiology had significantly higher CST. Plasma CST levels were similar between patients with preserved and reduced ejection fraction. Multivariable analysis showed that NYHA classes, the etiology of HF (ischemic or not) and estimated glomerular filtration rate independently predicted plasma LogCST levels (P<0.05). The area under ROC for CST and BNP in moderate to severe HF diagnosis was 0.626 and 0.831, respectively, combining CST and BNP did not improve the accuracy.
Collapse
Affiliation(s)
- Lin Liu
- Department of Cardiology, Peking University First Hospital, No. 1, Dahongluochang Street, West District, Beijing 100034, PR China
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Mazza R, Pasqua T, Cerra MC, Angelone T, Gattuso A. Akt/eNOS signaling and PLN S-sulfhydration are involved in H₂S-dependent cardiac effects in frog and rat. Am J Physiol Regul Integr Comp Physiol 2013; 305:R443-51. [PMID: 23785074 DOI: 10.1152/ajpregu.00088.2013] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Hydrogen sulfide (H₂S) has recently emerged as an important mediator of mammalian cardiovascular homeostasis. In nonmammalian vertebrates, little is known about the cardiac effects of H₂S. This study aimed to evaluate, in the avascular heart of the frog, Rana esculenta, whether and to what extent H₂S affects the cardiac performance, and what is the mechanism of action responsible for the observed effects. Results were analyzed in relation to those obtained in the rat heart, used as the mammalian model. Isolated and perfused (working and Langendorff) hearts, Western blot analysis, and modified biotin switch (S-sulfhydration) assay were used. In the frog heart, NaHS (used as H₂S donor, 10⁻¹²/10⁻⁷ M) dose-dependently decreased inotropism. This effect was reduced by glibenclamide (KATP channels blocker), NG-monomethyl-L-arginine (NOS inhibitor), 1H-[1,2,4] oxadiazolo-[4,3-a]quinoxalin-1-one (guanylyl cyclase inhibitor), KT₅₈₂₃ (PKG inhibitor), and it was blocked by Akt1/2 (Akt inhibitor) and by detergent Triton X-100. In the rat, in addition to the classic negative inotropic effect, NaHS (10⁻¹²/10⁻⁷ M) exhibited negative lusitropism. In both frog and rat hearts, NaHS treatment induced Akt and eNOS phosphorylation and an increased cardiac protein S-sulfhydration that, in the rat heart, includes phospholamban. Our data suggest that H₂S represents a phylogenetically conserved cardioactive molecule. Results obtained on the rat heart extend the role of H₂S also to cardiac relaxation. H₂S effects involve KATP channels, the Akt/NOS-cGMP/PKG pathway, and S-sulfhydration of cardiac proteins.
Collapse
Affiliation(s)
- Rosa Mazza
- Department of B.E.S.T. (Biology, Ecology and Earth Science), University of Calabria, Rende Italy
| | | | | | | | | |
Collapse
|
27
|
Liu L, Ding W, Zhao F, Shi L, Pang Y, Tang C. Plasma levels and potential roles of catestatin in patients with coronary heart disease. SCAND CARDIOVASC J 2013; 47:217-24. [DOI: 10.3109/14017431.2013.794951] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
|
28
|
Feng HZ, Chen X, Hossain MM, Jin JP. Toad heart utilizes exclusively slow skeletal muscle troponin T: an evolutionary adaptation with potential functional benefits. J Biol Chem 2012; 287:29753-64. [PMID: 22778265 PMCID: PMC3436204 DOI: 10.1074/jbc.m112.373191] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2012] [Revised: 07/02/2012] [Indexed: 11/06/2022] Open
Abstract
The three isoforms of vertebrate troponin T (TnT) are normally expressed in a muscle type-specific manner. Here we report an exception that the cardiac muscle of toad (Bufo) expresses exclusively slow skeletal muscle TnT (ssTnT) together with cardiac forms of troponin I and myosin as determined using immunoblotting, cDNA cloning, and/or LC-MS/MS. Using RT-PCR and 3'- and 5'-rapid amplification of cDNA ends on toad cardiac mRNA, we cloned full-length cDNAs encoding two alternatively spliced variants of ssTnT. Expression of the cloned cDNAs in Escherichia coli confirmed that the toad cardiac muscle expresses solely ssTnT, predominantly the low molecular weight variant with the exon 5-encoded NH(2)-terminal segment spliced out. Functional studies were performed in ex vivo working toad hearts and compared with the frog (Rana) hearts. The results showed that toad hearts had higher contractile and relaxation velocities and were able to work against a significantly higher afterload than that of frog hearts. Therefore, the unique evolutionary adaptation of utilizing exclusively ssTnT in toad cardiac muscle corresponded to a fitness value from improving systolic function of the heart. The data demonstrated a physiological importance of the functional diversity of TnT isoforms. The structure-function relationship of TnT may be explored for the development of new treatment of heart failure.
Collapse
Affiliation(s)
- Han-Zhong Feng
- From the Department of Physiology, Wayne State University School of
Medicine, Detroit, Michigan 48201
| | - Xuequn Chen
- From the Department of Physiology, Wayne State University School of
Medicine, Detroit, Michigan 48201
| | - M. Moazzem Hossain
- From the Department of Physiology, Wayne State University School of
Medicine, Detroit, Michigan 48201
| | - Jian-Ping Jin
- From the Department of Physiology, Wayne State University School of
Medicine, Detroit, Michigan 48201
| |
Collapse
|
29
|
Gaede AH, Inglott MA, Farnham MMJ, Pilowsky PM. Catestatin has an unexpected effect on the intrathecal actions of PACAP dramatically reducing blood pressure. Am J Physiol Regul Integr Comp Physiol 2012; 303:R719-26. [PMID: 22874427 DOI: 10.1152/ajpregu.00202.2012] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
This study focuses on presympathetic neurons of the rostral ventrolateral medulla (RVLM) that regulate sympathetic vasomotor tone. Many neurotransmitters are colocalized in RVLM neurons and are released under specific conditions to modulate efferent homeostatic responses. Of particular interest here are two peptides colocalized in catecholaminergic RVLM neurons: catestatin and pituitary adenylate cyclase-activating polypeptide (PACAP). Chromogranin A-derived catestatin is a potent endogenous noncompetitive nicotinic and adrenoreceptor antagonist. Catestatin impairs adenylate cyclase and phospholipase C action: mechanisms engaged by PACAP. Although PACAP and catestatin are likely coreleased, the possible effects of this are unknown. We aimed to determine whether catestatin affects the normal sympathoexcitatory but isotensive responses to intrathecal PACAP. Urethane-anesthetized, vagotomized, ventilated Sprague-Dawley rats (n = 22) were given an intrathecal injection of catestatin at different times prior to intrathecal administration of PACAP-38. Arterial pressure, splanchnic sympathetic nerve activity, heart rate, and reflex responses to baroreceptor and chemoreceptor activation were recorded. The key findings of this study are that pretreatment with catestatin time dependently enhances the PACAP-38 effect on mean arterial pressure and enhances sympathetic barosensitivity and chemosensitivity. The time-scale of the effect of catestatin on the response to PACAP-38 strongly suggests that catestatin is either causing changes in gene expression to exert its effects, or modifying intracellular mechanisms normally engaged by PAC(1) receptors. The ability of catestatin pretreatment to enhance barosensitivity and chemosensitivity after PACAP-38 injection supports the hypothesis that catestatin manipulates the intracellular environment within sympathetic neurons in a way that increases responses to PACAP.
Collapse
Affiliation(s)
- Andrea H Gaede
- The Australian School of Advanced Medicine, Macquarie Univ., Macquarie Park, NSW, Australia
| | | | | | | |
Collapse
|
30
|
Bandyopadhyay GK, Vu CU, Gentile S, Lee H, Biswas N, Chi NW, O'Connor DT, Mahata SK. Catestatin (chromogranin A(352-372)) and novel effects on mobilization of fat from adipose tissue through regulation of adrenergic and leptin signaling. J Biol Chem 2012; 287:23141-51. [PMID: 22535963 DOI: 10.1074/jbc.m111.335877] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Chromogranin A knock-out (Chga-KO) mice display increased adiposity despite high levels of circulating catecholamines and leptin. Consistent with diet-induced obese mice, desensitization of leptin receptors caused by hyperleptinemia is believed to contribute to the obese phenotype of these KO mice. In contrast, obesity in ob/ob mice is caused by leptin deficiency. To characterize the metabolic phenotype, Chga-KO mice were treated with the CHGA-derived peptide catestatin (CST) that is deficient in these mice. CST treatment reduced fat depot size and increased lipolysis and fatty acid oxidation. In liver, CST enhanced oxidation of fatty acids as well as their assimilation into lipids, effects that are attributable to the up-regulation of genes promoting fatty acid oxidation (Cpt1α, Pparα, Acox, and Ucp2) and incorporation into lipids (Gpat and CD36). CST did not affect basal or isoproterenol-stimulated cAMP production in adipocytes but inhibited phospholipase C activation by the α-adrenergic receptor (AR) agonist phenylephrine, suggesting inhibition of α-AR signaling by CST. Indeed, CST mimicked the lipolytic effect of the α-AR blocker phentolamine on adipocytes. Moreover, CST reversed the hyperleptinemia of Chga-KO mice and improved leptin signaling as determined by phosphorylation of AMPK and Stat3. CST also improved peripheral leptin sensitivity in diet-induced obese mice. In ob/ob mice, CST enhanced leptin-induced signaling in adipose tissue. In conclusion, our results implicate CST in a novel pathway that promotes lipolysis and fatty acid oxidation by blocking α-AR signaling as well as by enhancing leptin receptor signaling.
Collapse
|
31
|
Cardiac heterometric response: the interplay between Catestatin and nitric oxide deciphered by the frog heart. Nitric Oxide 2012; 27:40-9. [PMID: 22555002 DOI: 10.1016/j.niox.2012.04.003] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2012] [Revised: 03/19/2012] [Accepted: 04/16/2012] [Indexed: 01/20/2023]
Abstract
The length-active tension relation or heterometric regulation (Frank-Starling mechanism) is modulated by nitric oxide (NO) which, released in pulsatile fashion from the beating heart, improves myocardial relaxation and diastolic distensibility. The NO signaling is also implicated in the homeometric regulation exerted by extrinsic factors such as autonomic nervous system, endocrine and humoral agents. In the in vitro working frog heart, the Chromogranin A (CGA)-derived peptide, Catestatin (CTS; bovine CGA344-364), exerts a direct cardio-suppressive action through a NOS-NO-cGMP-mediated mechanism which requires the functional integrity of the endocardial endothelium (EE) and its endothelin-1 B type (ETB) receptor. However, functional interplay between NO and CTS and their role in the Frank-Starling response of the frog heart are lacking. Here we show that CTS improves the sensitivity to preload increases similar to that exerted by NO. This effect is abolished by inhibition of NO synthase (L-NAME), guanylate cyclase (ODQ), protein kinase G (KT5823), PI3K (Wortmannin), as well as by the functional damage of EE (Triton X-100) suggesting that CTS operates through an EE-dependent NO release. On the whole, the use of the avascular frog heart revealed the EE as major sensor-transducer interface between the physical (volume load) and chemical (CTS) stimuli, NO functioning as a connector between heterometric and homeometric regulation.
Collapse
|
32
|
Bartolomucci A, Possenti R, Mahata SK, Fischer-Colbrie R, Loh YP, Salton SRJ. The extended granin family: structure, function, and biomedical implications. Endocr Rev 2011; 32:755-97. [PMID: 21862681 PMCID: PMC3591675 DOI: 10.1210/er.2010-0027] [Citation(s) in RCA: 228] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
The chromogranins (chromogranin A and chromogranin B), secretogranins (secretogranin II and secretogranin III), and additional related proteins (7B2, NESP55, proSAAS, and VGF) that together comprise the granin family subserve essential roles in the regulated secretory pathway that is responsible for controlled delivery of peptides, hormones, neurotransmitters, and growth factors. Here we review the structure and function of granins and granin-derived peptides and expansive new genetic evidence, including recent single-nucleotide polymorphism mapping, genomic sequence comparisons, and analysis of transgenic and knockout mice, which together support an important and evolutionarily conserved role for these proteins in large dense-core vesicle biogenesis and regulated secretion. Recent data further indicate that their processed peptides function prominently in metabolic and glucose homeostasis, emotional behavior, pain pathways, and blood pressure modulation, suggesting future utility of granins and granin-derived peptides as novel disease biomarkers.
Collapse
Affiliation(s)
- Alessandro Bartolomucci
- Department of Integrative Biology and Physiology, University of Minnesota, Minneapolis, Minnesota 55455, USA
| | | | | | | | | | | |
Collapse
|
33
|
Gaede AH, Pilowsky PM. Catestatin, a chromogranin A-derived peptide, is sympathoinhibitory and attenuates sympathetic barosensitivity and the chemoreflex in rat CVLM. Am J Physiol Regul Integr Comp Physiol 2011; 302:R365-72. [PMID: 22129620 DOI: 10.1152/ajpregu.00409.2011] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Hypertension is a major cause of morbidity. The neuropeptide catestatin [human chromogranin A-(352-372)] is a peptide product of the vesicular protein chromogranin A. Studies in the periphery and in vitro studies show that catestatin blocks nicotine-stimulated catecholamine release and interacts with β-adrenoceptors and histamine receptors. Catestatin immunoreactivity is present in the rostral ventrolateral medulla (RVLM), a key site for blood pressure control in the brain stem. Recently, we reported that microinjection of catestatin into the RVLM is sympathoexcitatory and increases barosensitivity. Here, we report the effects of microinjection of catestatin (1 mM, 50 nl) into the caudal ventrolateral medulla (CVLM) in urethane-anesthetized, bilaterally vagotomized, artificially ventilated Sprague-Dawley rats (n = 8). We recorded resting arterial pressure, splanchnic sympathetic nerve activity, phrenic nerve activity, heart rate, and measured cardiovascular homeostatic reflexes. Homeostatic reflexes were evaluated by measuring cardiovascular responses to carotid baroreceptor and peripheral chemoreceptor activation. Catestatin decreased basal levels of arterial pressure (-23 ± 4 mmHg), sympathetic nerve activity (-26.6 ± 5.7%), heart rate (-19 ± 5 bpm), and phrenic nerve amplitude (-16.8 ± 3.3%). Catestatin caused a 15% decrease in phrenic inspiratory period (T(i)) and a 16% increase in phrenic expiratory period (T(e)) but had no net effect on the phrenic interburst interval (T(tot)). Catestatin decreased sympathetic barosensitivity by 63.6% and attenuated the peripheral chemoreflex (sympathetic nerve response to brief hypoxia; range decreased 39.9%; slope decreased 30.1%). The results suggest that catestatin plays an important role in central cardiorespiratory control.
Collapse
Affiliation(s)
- Andrea H Gaede
- Australian School of Advanced Medicine, Macquarie University, North Ryde, NSW, Australia
| | | |
Collapse
|
34
|
Meng L, Ye XJ, Ding WH, Yang Y, Di BB, Liu L, Huo Y. Plasma catecholamine release-inhibitory peptide catestatin in patients with essential hypertension. J Cardiovasc Med (Hagerstown) 2011; 12:643-7. [PMID: 21508845 DOI: 10.2459/jcm.0b013e328346c142] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
BACKGROUND Catestatin plays an important role in the adjustment of blood pressure and cardiac function. We investigated levels of plasma catestatin in essential hypertension and the relationship between catestatin and left ventricular hypertrophy. METHODS Plasma was collected from 136 patients with essential hypertension and 61 healthy controls. Plasma catestatin was measured by enzyme-linked immunosorbent assay (ELISA). Plasma norepinephrine was measured by high-performance liquid chromatography. All patients underwent echocardiography, measurement of fasting blood glucose, body mass index (BMI) and lipid levels. RESULTS Plasma levels of catestatin and norepinephrine were significantly higher in patients with essential hypertension than in normal controls (both P<0.01). The ratio of catestatin to norepinephrine was significantly lower in patients with essential hypertension than in normal controls (P<0.01). In patients with essential hypertension, plasma norepinephrine level was significantly higher in patients with than without left ventricular hypertrophy (P<0.01). Plasma catestatin level was lower, but not significantly, in patients with than without left ventricular hypertrophy. The ratio of catestatin to norepinephrine was significantly lower in patients with than without left ventricular hypertrophy (P<0.01). CONCLUSION Plasma catestatin is elevated in patients with essential hypertension. The ratio of catestatin to norepinephrine was lower in patients with left ventricular hypertrophy. Catestatin might participate in the development of hypertension and left ventricular hypertrophy.
Collapse
Affiliation(s)
- Lei Meng
- Department of Cardiology, Peking University First Hospital, Beijing, People's Republic of China
| | | | | | | | | | | | | |
Collapse
|
35
|
Angelone T, Quintieri AM, Pasqua T, Gentile S, Tota B, Mahata SK, Cerra MC. Phosphodiesterase type-2 and NO-dependent S-nitrosylation mediate the cardioinhibition of the antihypertensive catestatin. Am J Physiol Heart Circ Physiol 2011; 302:H431-42. [PMID: 22058158 DOI: 10.1152/ajpheart.00491.2011] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
The chromogranin A (CHGA)-derived peptide catestatin (CST: hCHGA(352-372)) is a noncompetitive catecholamine-release inhibitor that exerts vasodilator, antihypertensive, and cardiosuppressive actions. We have shown that CST directly influences the basal performance of the vertebrate heart where CST dose dependently induced a nitric oxide-cGMP-dependent cardiosuppression and counteracted the effects of adrenergic stimulation through a noncompetitive antagonism. Here, we sought to determine the specific intracardiac signaling activated by CST in the rat heart. Physiological analyses performed on isolated, Langendorff-perfused cardiac preparations revealed that CST-induced negative inotropism and lusitropism involve β(2)/β(3)-adrenergic receptors (β(2)/β(3)-AR), showing a higher affinity for β(2)-AR. Interaction with β(2)-AR activated phosphatidylinositol 3-kinase/endothelial nitric oxide synthase (eNOS), increased cGMP levels, and induced activation of phosphodiesterases type 2 (PDE2), which was found to be involved in the antiadrenergic action of CST as evidenced by the decreased cAMP levels. CST-dependent negative cardiomodulation was abolished by functional denudation of the endothelium with Triton. CST also increased the eNOS expression in cardiac tissue and human umbilical vein endothelial cells. cells, confirming the involvement of the vascular endothelium. In ventricular extracts, CST increased S-nitrosylation of both phospholamban and β-arrestin, suggesting an additional mechanism for intracellular calcium modulation and β-adrenergic responsiveness. We conclude that PDE2 and S-nitrosylation play crucial roles in the CST regulation of cardiac function. Our results are of importance in relation to the putative application of CST as a cardioprotective agent against stress, including excessive sympathochromaffin overactivation.
Collapse
Affiliation(s)
- Tommaso Angelone
- Department of Cell Biology, Laboratory of Cardiovascular Pathophysiology, University of Calabria, Arcavacata di Rende (CS), Italy.
| | | | | | | | | | | | | |
Collapse
|
36
|
Guo X, Zhou C, Sun N. The neuropeptide catestatin promotes vascular smooth muscle cell proliferation through the Ca2+-calcineurin-NFAT signaling pathway. Biochem Biophys Res Commun 2011; 407:807-12. [PMID: 21443864 DOI: 10.1016/j.bbrc.2011.03.104] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2011] [Accepted: 03/22/2011] [Indexed: 12/12/2022]
Abstract
The Chromogranin A-derived neuropeptide catestatin is an endogenous nicotinic cholinergic antagonist that acts as a pleiotropic hormone. Since catestatin shares several functions with other members derived from the chromogranin/secretogranin protein family and other neuropeptides which exert proliferative effects on vascular smooth muscle cells (VSMCs), we therefore hypothesized that catestatin would regulate VSMC proliferation. The present study demonstrates that catestatin caused a dose-dependent induction of proliferation in rat aortic smooth muscle cells and furthermore evoked a sustained increase in intracellular calcium. This subsequently leaded to enhanced activation of the Ca(2+)/calmodulin-dependent phosphatase, calcineurin and resulted in an activation of the Ca(2+)-dependent transcription factor, nuclear factor of activated T cells (NFAT), initiating transcription of proliferative genes. In addition, cyclosporin A (CsA), a potent inhibitor of calcineurin, abrogated catestatin-mediated effect on VSMCs, indicating that the calcineurin-NFAT signaling is strongly required for catestatin-induced growth of VSMCs. The present study establishes catestatin as a novel proliferative cytokine on vascular smooth muscle cells and this effect is mediated by the Ca(2+)-calcineurin-NFAT signaling pathway.
Collapse
Affiliation(s)
- Xiaoxia Guo
- Department of Cardiology, People's Hospital, Peking University, No. 11 South Avenue, Xi Zhi Men Xicheng District, Beijing 100044, China
| | | | | |
Collapse
|
37
|
Imbrogno S, Garofalo F, Cerra MC, Mahata SK, Tota B. The catecholamine release-inhibitory peptide catestatin (chromogranin A344-363) modulates myocardial function in fish. ACTA ACUST UNITED AC 2011; 213:3636-43. [PMID: 20952611 DOI: 10.1242/jeb.045567] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Catestatin (CST), the 21-amino acid, cationic and hydrophobic peptide proteolytically derived from the ubiquitous chromogranin A (CgA), is an endogenous inhibitor of catecholamine release, a potent vasodilator in vivo and an anti-hypertensive agent in mammals, including humans. Recently, we discovered that CST also functions as an important negative modulator of heart performance in frog and rat. To gain an evolutionary perspective on CST cardiotropism in fish, we analysed the influence of bovine CST (CgA₃₄₄₋₃₆₄) on the eel heart, as well as the eventual species-specific mechanisms of its myocardial action. Experiments were carried out on fresh-water eels (Anguilla anguilla L.) using an electrically paced isolated working heart preparation. Stroke volume and stroke work were used as measures of ventricular performance. Under basal conditions, CST (from 11 nmol l⁻¹ to 165 nmol l⁻¹) caused a concentration-dependent negative inotropism, which was abolished by inhibitors of either β₁/β₂ (propranolol) or β₃ (SR₅₉₂₃₀) adrenergic receptors, or by G(i/o) protein (PTx) or nitric oxide synthase (L-NMMA), or guanylate cyclase (ODQ) blockers. This suggests a β-adrenergic receptor-G(i/o) protein-NO-cGMP-dependent mechanism. By contrast, the CST-induced cardio-suppression was not influenced by atropine, unspecific muscarinic antagonist, thus excluding cholinergic receptor involvement. CST also counteracted the adrenergic (isoproterenol)-mediated positive inotropism. Under increased preload (i.e. Frank-Starling response) conditions, CST induced a significant increase of the Frank-Starling response, which was blocked by L-NMMA and thapsigargin, but independent from guanylate cyclase. In conclusion, this is the first report in fish that CST modulates myocardial performance under basal, as well as under increased preload, conditions and counteracts the adrenergic-mediated positive inotropism, which strikingly supports the evolutionary significance and establishes the cardioactive role of this peptide.
Collapse
Affiliation(s)
- Sandra Imbrogno
- Department of Cell Biology, University of Calabria, 87030 Arcavacata di Rende (CS), Italy
| | | | | | | | | |
Collapse
|
38
|
Mahata SK, Mahata M, Fung MM, O'Connor DT. Reprint of: Catestatin: a multifunctional peptide from chromogranin A. REGULATORY PEPTIDES 2010; 165:52-62. [PMID: 20965217 PMCID: PMC10838673 DOI: 10.1016/j.regpep.2010.09.007] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
In 1997, we identified a novel peptide, catestatin (CST: bovine chromogranin A [CHGA]₃₄₄₋₃₆₄: RSMRLSFRARGYGFRGPGLQL; human CHGA₃₅₂₋₃₇₂: SSMKLSFRARGYGFRGPGPQL), which is a potent inhibitor of nicotinic-cholinergic-stimulated catecholamine secretion. CST shows characteristic inhibitory effects on nicotinic cationic (Na+, Ca²+) signal transduction, which are specific to the neuronal nicotinic receptor. Utilizing systematic polymorphism discovery at the human CHGA locus we discovered three human variants of CST: G³⁶⁴S, P³⁷⁰L, and R³⁷⁴Q that showed differential potencies towards the inhibition of catecholamine secretion. In humans, CHGA is elevated and its processing to CST is diminished in hypertension. Diminished CST is observed not only in hypertensive individuals but also in the early-normotensive offspring of patients with hypertension, suggesting that an early deficiency of CST might play a pathogenic role in the subsequent development of the disease. Consistent with human findings, prevention of endogenous CST expression by targeted ablation (knockout) of the mouse Chga locus (Chga-KO) resulted in severe hypertension that can be "rescued" specifically by replacement of the CST peptide. CST acts directly on the heart to inhibit the inotropic and lusitropic properties of the rodent heart and also acts as a potent vasodilator in rats and humans. While the G³⁶⁴S CST variant caused profound changes in human autonomic activity and seemed to reduce the risk of developing hypertension, CST replacement rescued Chga-KO mice from dampened baroreflex sensitivity. In addition, CST has been shown to induce chemotaxis and acts as an antimicrobial as well as an antimalarial peptide. The present review summarizes these multiple actions of CST.
Collapse
Affiliation(s)
- Sushil K Mahata
- Department of Medicine (0838), University of California at San Diego, and Veterans Affairs San Diego Healthcare System, 9500 Gilman Drive, La Jolla, CA 92093-0838, USA.
| | | | | | | |
Collapse
|
39
|
Tota B, Cerra MC, Gattuso A. Catecholamines, cardiac natriuretic peptides and chromogranin A: evolution and physiopathology of a 'whip-brake' system of the endocrine heart. ACTA ACUST UNITED AC 2010; 213:3081-103. [PMID: 20802109 DOI: 10.1242/jeb.027391] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
In the past 50 years, extensive evidence has shown the ability of vertebrate cardiac non-neuronal cells to synthesize and release catecholamines (CA). This formed the mindset behind the search for the intrinsic endocrine heart properties, culminating in 1981 with the discovery of the natriuretic peptides (NP). CA and NP, co-existing in the endocrine secretion granules and acting as major cardiovascular regulators in health and disease, have become of great biomedical relevance for their potent diagnostic and therapeutic use. The concept of the endocrine heart was later enriched by the identification of a growing number of cardiac hormonal substances involved in organ modulation under normal and stress-induced conditions. Recently, chromogranin A (CgA), a major constituent of the secretory granules, and its derived cardio-suppressive and antiadrenergic peptides, vasostatin-1 and catestatin, were shown as new players in this framework, functioning as cardiac counter-regulators in 'zero steady-state error' homeostasis, particularly under intense excitatory stimuli, e.g. CA-induced myocardial stress. Here, we present evidence for the hypothesis that is gaining support, particularly among human cardiologists. The actions of CA, NP and CgA, we argue, may be viewed as a hallmark of the cardiac capacity to organize 'whip-brake' connection-integration processes in spatio-temporal networks. The involvement of the nitric oxide synthase (NOS)/nitric oxide (NO) system in this configuration is discussed. The use of fish and amphibian paradigms will illustrate the ways that incipient endocrine-humoral agents have evolved as components of cardiac molecular loops and important intermediates during evolutionary transitions, or in a distinct phylogenetic lineage, or under stress challenges. This may help to grasp the old evolutionary roots of these intracardiac endocrine/paracrine networks and how they have evolved from relatively less complicated designs. The latter can also be used as an intellectual tool to disentangle the experimental complexity of the mammalian and human endocrine hearts, suggesting future investigational avenues.
Collapse
Affiliation(s)
- Bruno Tota
- Department of Cell Biology, University of Calabria, 87030, Arcavacata di Rende, Italy.
| | | | | |
Collapse
|
40
|
Fung MM, Salem RM, Mehtani P, Thomas B, Lu CF, Perez B, Rao F, Stridsberg M, Ziegler MG, Mahata SK, O'Connor DT. Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo. Clin Exp Hypertens 2010; 32:278-87. [PMID: 20662728 DOI: 10.3109/10641960903265246] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Catestatin is a bioactive peptide of chromogranin A (CHGA) that is co-released with catecholamines from secretory vesicles. Catestatin may function as a vasodilator and is diminished in hypertension. To evaluate this potential vasodilator in vivo without systemic counterregulation, we infused catestatin to target concentrations of approximately 50, approximately 500, approximately 5000 nM into dorsal hand veins of 18 normotensive men and women, after pharmacologic venoconstriction with phenylephrine. Pancreastatin, another CHGA peptide, was infused as a negative control. After preconstriction to approximately 69%, increasing concentrations of catestatin resulted in dose-dependent vasodilation (P = 0.019), in female subjects (to approximately 44%) predominantly. The EC(50) (approximately 30 nM) for vasodilation induced by catestatin was the same order of magnitude to circulating endogenous catestatin (4.4 nM). No vasodilation occurred during the control infusion with pancreastatin. Plasma CHGA, catestatin, and CHGA-to-catestatin processing were then determined in 622 healthy subjects without hypertension. Female subjects had higher plasma catestatin levels than males (P = 0.001), yet lower CHGA precursor concentrations (P = 0.006), reflecting increased processing of CHGA-to-catestatin (P < 0.001). Our results demonstrate that catestatin dilates human blood vessels in vivo, especially in females. Catestatin may contribute to sex differences in endogenous vascular tone, thereby influencing the complex predisposition to hypertension.
Collapse
Affiliation(s)
- Maple M Fung
- Department of Medicine, University of California at San Diego and Veterans Affairs, San Diego Healthcare System, La Jolla, California, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Biswas N, Curello E, O’Connor DT, Mahata SK. Chromogranin/secretogranin proteins in murine heart: myocardial production of chromogranin A fragment catestatin (Chga(364-384)). Cell Tissue Res 2010; 342:353-61. [PMID: 21052719 PMCID: PMC2996542 DOI: 10.1007/s00441-010-1059-4] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2010] [Accepted: 09/10/2010] [Indexed: 02/06/2023]
Abstract
In the heart, the secretory granules containing the atrial natriuretic peptides (ANP) and B-type myocardial natriuretic peptide (BNP) provide the basis for the endocrine function of this organ. We sought to determine whether atrial and myocardial secretory granules contain chromogranin/secretogranin proteins including chromogranin A (CHGA/Chga), chromogranin B (CHGB/Chgb) and secretogranin II (SCG2/Scg2). Deconvolution microscopy on immunolabeled proteins revealed the presence of Chga, Chgb, and Scg2 in murine cardiac secretory granules. The presence of low plasma catestatin (CST: mChga364–384) in older mice indicates diminished processing of Chga to CST with advancement of age, which is comparable to that found in humans. We have previously shown that CST (hCHGA352–372) exerts potent cardio-suppressive effects on frog and rat heart, but the source of CST for such action has remained elusive. In the present study, we found CST-related peptides in cardiomyocytes and in heart, which establishes an autocrine/paracrine function of CST in cardiac tissue. We conclude that cardiac secretory granules contain Chga, Chgb and Scg2 and that Chga is processed to CST in murine heart.
Collapse
Affiliation(s)
- Nilima Biswas
- Department of Medicine (0838), UCSD School of Medicine and VASDHS, 9500 Gilman Drive, La Jolla, CA 92093-0838 USA
| | - Erica Curello
- Department of Medicine (0838), UCSD School of Medicine and VASDHS, 9500 Gilman Drive, La Jolla, CA 92093-0838 USA
- Molecular Genetics, University of California, San Diego, CA USA
- VA San Diego Healthcare System, 9500 Gilman Drive, La Jolla, CA 92093-0838 USA
| | - Daniel T. O’Connor
- Department of Medicine (0838), UCSD School of Medicine and VASDHS, 9500 Gilman Drive, La Jolla, CA 92093-0838 USA
- Molecular Genetics, University of California, San Diego, CA USA
- VA San Diego Healthcare System, 9500 Gilman Drive, La Jolla, CA 92093-0838 USA
| | - Sushil K. Mahata
- Department of Medicine (0838), UCSD School of Medicine and VASDHS, 9500 Gilman Drive, La Jolla, CA 92093-0838 USA
- VA San Diego Healthcare System, 9500 Gilman Drive, La Jolla, CA 92093-0838 USA
| |
Collapse
|
42
|
Mazza R, Angelone T, Pasqua T, Gattuso A. Physiological evidence for β3-adrenoceptor in frog (Rana esculenta) heart. Gen Comp Endocrinol 2010; 169:151-7. [PMID: 20709064 DOI: 10.1016/j.ygcen.2010.08.003] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/17/2010] [Revised: 08/03/2010] [Accepted: 08/06/2010] [Indexed: 11/30/2022]
Abstract
β3-Adrenergic receptors (ARs) have been recently identified in mammalian hearts where, unlike β1- and β2-ARs, induce cardio-suppressive effects. The aim of this study was to describe β3-AR role in the frog (Rana esculenta) heart and to examine its signal transduction pathway. The presence of β3-AR, by using Western blotting analysis, has been also identified. BRL(37344), a selective β3-AR agonist, induced a dose-dependent negative inotropic effect at concentrations from 10(-12) to 10(-6)M. This effect was not modified by nadolol (β1/β2-AR antagonist) and by phentolamine (α-AR antagonist), but it was suppressed by the β3-AR-specific antagonist SR(59230) and by exposure to the Gi/o proteins inhibitor Pertussis Toxin. In addition, the involvement of EE-NOS-cGMP-PKG/PDE2 pathway in the negative inotropism of BRL(37344) has been assessed. BRL(37344) treatment induced eNOS and Akt phosphorylation as well as an increase of cGMP levels. β3-ARs activation induce a non-competitive antagonism against ISO stimulation which disappeared in presence of PKG and PDE2 inhibition. Taken together our findings provide, for the first time in the frog, a role for β3-ARs in the cardiac performance modulation which involves Gi/o protein and occurs via an EE-NO-cGMP-PKG/PDE2 cascade.
Collapse
Affiliation(s)
- Rosa Mazza
- Department of Cell Biology, University of Calabria, Arcavacata di Rende (CS), Italy
| | | | | | | |
Collapse
|
43
|
Gaede AH, Pilowsky PM. Catestatin in rat RVLM is sympathoexcitatory, increases barosensitivity, and attenuates chemosensitivity and the somatosympathetic reflex. Am J Physiol Regul Integr Comp Physiol 2010; 299:R1538-45. [PMID: 20926765 DOI: 10.1152/ajpregu.00335.2010] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The fundamental role and corollary effects of neuropeptides that govern cardiorespiratory control in the brain stem are poorly understood. One such regulatory peptide, catestatin [Cts, human chromogranin A-(352-372)], noncompetitively inhibits nicotinic-cholinergic-stimulated catecholamine release. Previously, we demonstrated the presence of chromogranin A mRNA in brain stem neurons that are important for the maintenance of arterial pressure. In the present study, using immunofluorescence histochemistry, we show that Cts immunoreactivity is colocalized with tyrosine hydroxylase in C1 neurons of the rostral ventrolateral medulla (RVLM, n = 3). Furthermore, we investigated the effects of Cts on resting blood pressure, splanchnic sympathetic nerve activity, phrenic nerve activity, heart rate, and adaptive reflexes. Cts (1 mM in 50 nl or 100 μM in 50-100 nl) was microinjected into the RVLM in urethane-anesthetized, vagotomized, ventilated Sprague-Dawley rats (n = 19). Cardiovascular responses to stimulation of carotid baroreceptors, peripheral chemoreceptors, and the sciatic nerve (somatosympathetic reflex) were analyzed. Cts (1 mM in 50 nl) increased resting arterial pressure (28 ± 3 mmHg at 2 min postinjection), sympathetic nerve activity (15 ± 3% at 2 min postinjection), and phrenic discharge amplitude (31 ± 4% at 10 min postinjection). Cts increased sympathetic barosensitivity 40% (slope increased from -0.05 ± 0.01 before Cts to -0.07 ± 0.01 after Cts) and attenuated the somatosympathetic reflex [1st peak: 36% (from 132 ± 32.1 to 84.0 ± 17.0 μV); 2nd peak: 44% (from 65.1 ± 21.4 to 36.6 ± 14.1 μV)] and chemoreflex (blood pressure response to anoxia decreased 55%, sympathetic response decreased 46%). The results suggest that Cts activates sympathoexcitatory bulbospinal neurons in the RVLM and plays an important regulatory role in adaptive reflexes.
Collapse
Affiliation(s)
- Andrea H Gaede
- Australian School of Advanced Medicine, Macquarie Univ., NSW 2109, Australia
| | | |
Collapse
|
44
|
Brar BK, Helgeland E, Mahata SK, Zhang K, O'Connor DT, Helle KB, Jonassen AK. Human catestatin peptides differentially regulate infarct size in the ischemic-reperfused rat heart. ACTA ACUST UNITED AC 2010; 165:63-70. [PMID: 20655339 DOI: 10.1016/j.regpep.2010.07.153] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2009] [Revised: 06/29/2010] [Accepted: 07/08/2010] [Indexed: 01/06/2023]
Abstract
In acute myocardial infarction increased plasma levels of chromogranin A are correlated with decreased survival. At the human chromogranin A gene locus there are two naturally occurring amino acid substitution variants within the catestatin region, i.e. Gly³⁶⁴Ser and Pro³⁷⁰Leu, displaying differential potencies towards inhibition of nicotinic cholinergic agonist-evoked catecholamine secretion from sympathochromaffin cells and different degrees of processing from the prohormone. Here, we examine whether two of the variants and the wild type catestatin may affect the development of infarct size during ischemic reperfusion in the Langendorff rat heart model. The hearts were subjected to regional ischemia followed by reperfusion in the presence or absence of synthetic variants of human catestatin. Compared to the Gly³⁶⁴Ser variant both the wild type and Pro³⁷⁰Leu variants increased infarct size while decreasing the cardiac levels of phosphorylated Akt and two of its downstream targets, FoxO1 and BAD. In conclusion, these findings suggest that, in contrast to the Gly³⁶⁴Ser variant, wild type catestatin and the Pro³⁷⁰Leu variant (allele frequency ~0.3%) increased myocardial infarct size via a mechanism involving dephosphorylation of Akt and the two downstream targets during ischemic reperfusion in the isolated rat heart.
Collapse
|
45
|
Dalzell JR, Jackson CE, McDonagh TA, Gardner RS. Novel biomarkers in heart failure: an overview. Biomark Med 2010; 3:453-63. [PMID: 20477516 DOI: 10.2217/bmm.09.42] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Heart failure is a complex systemic syndrome resulting from significant impairment of cardiac function. A vast array of biological pathways is now known to be involved in heart failure, including deleterious pathways promoting its development and progression, as well as compensatory cardioprotective pathways. Some of the components of these pathways are now recognized as biomarkers of this condition, and can aid diagnosis, prognostication and guide management. As the understanding of the pathophysiology of heart failure progresses, further candidate biomarkers are being identified. This article reviews the literature regarding the more recently identified biomarkers and outlines areas requiring further study.
Collapse
Affiliation(s)
- Jonathan R Dalzell
- British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, G12 8TA, UK.
| | | | | | | |
Collapse
|
46
|
Mazza R, Imbrogno S, Tota B. The interplay between chromogranin A-derived peptides and cardiac natriuretic peptides in cardioprotection against catecholamine-evoked stress. ACTA ACUST UNITED AC 2010; 165:86-94. [PMID: 20594992 DOI: 10.1016/j.regpep.2010.05.005] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2009] [Revised: 05/20/2010] [Accepted: 05/25/2010] [Indexed: 11/26/2022]
Abstract
Chromogranin A (CgA) is the major soluble protein co-stored and co-released with catecholamines (CAs) from secretory vesicles in the adrenal medulla chromaffin cells. Present in the diffuse neuroendocrine system, it has also been detected in rat and human cardiac secretory granules where it co-stores with natriuretic peptide hormones (NPs). Mounting evidence shows that CgA is a marker of cardiovascular dysfunctions (essential hypertension, hypertrophic and dilatative cardiomyopathy, heart failure) and precursor of the cardioactive peptides vasostatin-1 (VS-1) and catestatin (Cts). This review focuses on recent knowledge regarding the myocardial, coronary and anti-adrenergic actions of VS-1. In particular, the negative inotropism, lusitropism and coronary dilation effects of rat CgA1-64 (rCgA) and human recombinant STACgA1-78 (hrSTACgA1-78) are summarized with attention on their counteracting isoproterenol- and endothelin-1-induced positive inotropism, as well as ET-1-dependent coronary constriction. The interactions between vasostatins (VSs), NPs and CA receptors are proposed as a paradigm of the heart capacity to organize complex connection-integration processes for maintaining homeostasis under intense cardio-excitatory stimuli (myocardial stress).
Collapse
Affiliation(s)
- Rosa Mazza
- Dept of Cell Biology, University of Calabria, 87030 Arcavacata di Rende (CS), Italy.
| | | | | |
Collapse
|
47
|
Dev NB, Gayen JR, O'Connor DT, Mahata SK. Chromogranin a and the autonomic system: decomposition of heart rate variability and rescue by its catestatin fragment. Endocrinology 2010; 151:2760-8. [PMID: 20410203 PMCID: PMC2875835 DOI: 10.1210/en.2009-1110] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Chromogranin A (CHGA/Chga) has been implicated in the genesis of systemic hypertension and consequent cardiac abnormalities. Catestatin (CST) (human CHGA(352-372)) replacement reduces blood pressure elevation and increases baroreflex sensitivity in Chga knockout (KO) mice. Because of the dampened baroreflex sensitivity, we reasoned that KO mice would display altered heart rate variability (HRV). Thus, we evaluated beat-to-beat measurements in HRV in wild-type (WT) and KO mice, before and after CST replacement. HR dynamics were evaluated by bipolar Einthoven electrocardiogram, with deconvolution into time and frequency domains, as well as Lorenz nonlinear return analyses. At baseline, HR was higher [444 +/- 24 beats per minute (bpm)] in KO compared with WT (330 +/- 18 bpm) mice. The total power in the HRV spectra was substantially diminished in KO animals. CST increased total power but only in KO mice. Each time-domain parameter was substantially lower in KO compared with WT mice, and the CST in the KO group could reverse the differences. Lorenz analysis revealed reductions in S1 (short axis perpendicular to the line of identity in the ellipse) and S2 (long axis along the line of identity in the ellipse) in KO animals, indicating that regulation of HRV is diminished in the parasympathetic and sympathetic domains. CST replacement caused restoration of both S1 and S2, in the KO group. These data suggest that Chga has a profound effect on autonomic tone to the heart and that its CST fragment is responsible for such actions. The results suggest future strategies for intervention in cardiovascular disorders accompanied by adverse HRV profiles.
Collapse
Affiliation(s)
- Nagendu B Dev
- Department of Medicine (0838), University of California, San Diego, and Veterans Affairs San Diego Healthcare System, 9500 Gilman Drive, La Jolla, California 92093-0838, USA
| | | | | | | |
Collapse
|
48
|
Dondossola E, Gasparri A, Bachi A, Longhi R, Metz-Boutigue MH, Tota B, Helle KB, Curnis F, Corti A. Role of vasostatin-1 C-terminal region in fibroblast cell adhesion. Cell Mol Life Sci 2010; 67:2107-18. [PMID: 20217454 PMCID: PMC11115572 DOI: 10.1007/s00018-010-0319-5] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2009] [Revised: 02/09/2010] [Accepted: 02/17/2010] [Indexed: 10/19/2022]
Abstract
Fibroblast adhesion can be modulated by proteins released by neuroendocrine cells and neurons, such as chromogranin A (CgA) and its N-terminal fragment vasostatin-1 (VS-1, CgA(1-78)). We have investigated the mechanisms of the interaction of VS-1 with fibroblasts and of its pro-adhesive activity and have found that the proadhesive activity of VS-1 relies on its interaction with the fibroblast membrane via a phospholipid-binding amphipathic alpha-helix located within residues 47-66, as well as on the interaction of the adjacent C-terminal region 67-78, which is structurally similar to ezrin-radixin-moesin-binding phosphoprotein 50 (a membrane-cytoskeleton adapter protein), with other cellular components critical for the regulation of cell cytoskeleton.
Collapse
Affiliation(s)
- Eleonora Dondossola
- Division of Molecular Oncology and IIT Network Research Unit of Molecular Neuroscience, San Raffaele Scientific Institute, via Olgettina 58, 20132 Milan, Italy
| | - Anna Gasparri
- Division of Molecular Oncology and IIT Network Research Unit of Molecular Neuroscience, San Raffaele Scientific Institute, via Olgettina 58, 20132 Milan, Italy
| | - Angela Bachi
- Division of Molecular Oncology and IIT Network Research Unit of Molecular Neuroscience, San Raffaele Scientific Institute, via Olgettina 58, 20132 Milan, Italy
| | | | | | - Bruno Tota
- Department of Cell Biology, University of Calabria, Cosenza, Italy
| | - Karen B. Helle
- Department of Biomedicine, University of Bergen, Bergen, Norway
| | - Flavio Curnis
- Division of Molecular Oncology and IIT Network Research Unit of Molecular Neuroscience, San Raffaele Scientific Institute, via Olgettina 58, 20132 Milan, Italy
| | - Angelo Corti
- Division of Molecular Oncology and IIT Network Research Unit of Molecular Neuroscience, San Raffaele Scientific Institute, via Olgettina 58, 20132 Milan, Italy
| |
Collapse
|
49
|
Sahu BS, Sonawane PJ, Mahapatra NR. Chromogranin A: a novel susceptibility gene for essential hypertension. Cell Mol Life Sci 2010; 67:861-74. [PMID: 19943077 PMCID: PMC11115493 DOI: 10.1007/s00018-009-0208-y] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2009] [Revised: 11/06/2009] [Accepted: 11/06/2009] [Indexed: 12/25/2022]
Abstract
Chromogranin A (CHGA) is ubiquitously expressed in secretory cells of the endocrine, neuroendocrine, and neuronal tissues. Although this protein has long been known as a marker for neuroendocrine tumors, its role in cardiovascular disease states including essential hypertension (EH) has only recently been recognized. It acts as a prohormone giving rise to bioactive peptides such as vasostatin-I (human CHGA(1-76)) and catestatin (human CHGA(352-372)) that exhibit several cardiovascular regulatory functions. CHGA is over-expressed but catestatin is diminished in EH. Moreover, genetic variants in the promoter, catestatin, and 3'-untranslated regions of the human CHGA gene alter autonomic activity and blood pressure. Consistent with these findings, targeted ablation of this gene causes severe arterial hypertension and ventricular hypertrophy in mice. Transgenic expression of the human CHGA gene or exogenous administration of catestatin restores blood pressure in these mice. Thus, the accumulated evidence establishes CHGA as a novel susceptibility gene for EH.
Collapse
Affiliation(s)
- Bhavani S. Sahu
- Cardiovascular Genetics Laboratory, Department of Biotechnology, Indian Institute of Technology Madras, Chennai, 600036 India
| | - Parshuram J. Sonawane
- Cardiovascular Genetics Laboratory, Department of Biotechnology, Indian Institute of Technology Madras, Chennai, 600036 India
| | - Nitish R. Mahapatra
- Cardiovascular Genetics Laboratory, Department of Biotechnology, Indian Institute of Technology Madras, Chennai, 600036 India
| |
Collapse
|
50
|
Helle KB. The chromogranin A-derived peptides vasostatin-I and catestatin as regulatory peptides for cardiovascular functions. Cardiovasc Res 2010; 85:9-16. [PMID: 19640932 DOI: 10.1093/cvr/cvp266] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
A range of inflammatory conditions is associated with pathologically high levels of circulating chromogranin A (CgA). This prohormone belongs to the family of uniquely acidic proteins co-stored and co-secreted with other hormones and peptides from the diffuse neuroendocrine system. Two highly conserved, CgA-derived peptides, vasostatin-I and catestatin, have been implicated as modulators of a wide range of cells and tissues, including those of the cardiovascular system. This review focuses on links between elevated circulating CgA and cardiovascular dysfunctions in inflammatory conditions in relation to potential beneficial effects of vasostatin-I and catestatin. Characteristic membrane-penetrating properties have been assigned to both peptides, and pertussis toxin sensitivity is shared by a number of their responses, notably in the vascular and cardiac endothelium. Pertussis toxin-sensitive, receptor-independent activation via heterotrimeric G proteins and Galphai/o subunits will be discussed as possible mechanisms for inhibitory effects of vasostatin-I and catestatin on vascular and cardiac responses. The accumulated evidence provides convincing support for vasostatin-I and catestatin as regulatory peptides for the cardiovascular system, converging on alleviation of significant dysfunctions as part of several inflammatory conditions.
Collapse
Affiliation(s)
- Karen B Helle
- Department of Biomedicine, University of Bergen, Jonas Lies vei 91, Bergen, Norway.
| |
Collapse
|